Colorectal cancer and defects in the mismatch repair and base excision repair systems by Enholm, Susa
        
 
 
Helsinki University Biomedical Dissertations No. 43 
 
 
 
 
COLORECTAL CANCER AND 
DEFECTS IN THE MISMATCH REPAIR AND  
BASE EXCISION REPAIR SYSTEMS 
 
 
 
 
 
Susa Enholm 
 
 
Department of Medical Genetics 
Molecular and Cancer Biology Programme 
Haartman Institute and Biomedicum Helsinki 
University of Helsinki 
Finland 
 
 
 
 
 
Academic dissertation 
 
To be publicly discussed, with the permission of the Medical Faculty of the 
University of Helsinki, in the lecture hall 3, Biomedicum Helsinki, Haartmaninkatu 8, 
on 16 January 2004, at 12 noon. 
 
Helsinki 2004 
 Supervised by 
 
Lauri A. Aaltonen, MD, PhD 
Research Professor of the Finnish Academy of Sciences 
Department of Medical Genetics 
Haartman Institute and Biomedicum Helsinki 
University of Helsinki 
Finland 
 
Auli Karhu, PhD 
Department of Medical Genetics 
Haartman Institute and Biomedicum Helsinki 
University of Helsinki 
Finland 
 
Reviewed by 
 
Anne Kallioniemi, MD, PhD 
Docent 
Laboratory of Cancer Genetics 
Institute of Medical Technology 
University of Tampere 
Finland 
 
Minna Nyström-Lahti, PhD 
Docent 
Division of Genetics 
Department of Biosciences 
University of Helsinki 
Finland 
 
Official opponent 
 
Tapio Visakorpi, MD, PhD 
Professor of Cancer Genetics 
Institute of Medical Technology 
University of Tampere 
Finland 
 
 
 
 
 
 
 
ISBN 952-10-1493-8 (paperback) 
ISBN 952-10-1494-6 (PDF) 
ISSN 1457-8433 
http://ethesis.helsinki.fi 
Yliopistopaino 
Helsinki 2004 
 CONTENTS 
 
 
 
 
ABBREVIATIONS.......................................................................................................5 
LIST OF ORIGINAL PUBLICATIONS .....................................................................7 
ABSTRACT ..................................................................................................................8 
REVIEW OF THE LITERATURE .............................................................................9 
1. SUSCEPTIBILITY TO CANCER......................................................................................9 
1.1 Oncogenes and tumour suppressor genes .......................................................9 
1.2 Epigenetic mechanisms ...............................................................................10 
1.3 High- and low-penetrance genes..................................................................10 
2. COLORECTAL CANCER ............................................................................................11 
2.1 Non-polyposis and polyposis syndromes .....................................................11 
2.1.1 Hereditary non-polyposis colorectal cancer ........................................11 
2.1.2 Familial adenomatous polyposis.........................................................13 
2.1.3 MYH-associated polyposis..................................................................14 
2.2 Low-penetrance genes for colorectal cancer.................................................14 
3. MODELS FOR COLORECTAL CANCER FORMATION .....................................................15 
3.1 From adenoma to carcinoma........................................................................15 
3.2 Tumour clock model ...................................................................................17 
4. DNA REPAIR..........................................................................................................18 
4.1 Mechanisms of DNA repair .........................................................................18 
4.2 DNA repair disorders ..................................................................................19 
5. COLORECTAL CANCER-CAUSING GENES IN MISMATCH REPAIR AND BASE EXCISION 
REPAIR SYSTEMS ........................................................................................................19 
5.1 Mismatch repair mechanism........................................................................19 
5.1.1 Defects in mismatch repair genes .......................................................22 
5.1.1.1 MLH1 and MSH2 ...................................................................22 
5.1.1.2 MSH6 and MSH3 ...................................................................22 
5.1.1.3 PMS1 and PMS2 ....................................................................23 
5.1.1.4 MLH3 ....................................................................................23 
5.1.1.5 EXO1 .....................................................................................23 
5.1.2 Inactivation of mismatch repair genes.................................................24 
5.1.3 Microsatellite instability.....................................................................24 
5.1.3.1 Microsatellite instability target genes......................................25 
5.2 Base excision repair mechanism ..................................................................27 
5.2.1 Defects in base excision repair genes..................................................28 
5.2.1.1 MYH ......................................................................................29 
AIMS OF THE STUDY..............................................................................................30 
MATERIALS AND METHODS ................................................................................31 
1. PATIENTS AND DNA SAMPLES ................................................................................31 
1.1 MLH1-/- patient (I) .......................................................................................31 
1.2 Colorectal carcinoma patients (II-V)............................................................31 
1.2.1 Searching for microsatellite instability target genes (II) ......................31 
 1.2.2 MLH3 analysis (III)............................................................................31 
1.2.3 EXO1 analysis (IV) ............................................................................31 
1.2.4 MYH analysis (V)...............................................................................32 
1.3 Control individuals (I, III-V) .......................................................................32 
1.4 DNA extraction (I-V) ..................................................................................32 
2. STUDY OF THE MLH1-/- PATIENT (I).........................................................................33 
2.1 MLH1 mutation 1 analysis...........................................................................33 
2.2 Microsatellite analysis .................................................................................33 
3. SEARCH FOR MICROSATELLITE INSTABILITY TARGET GENES (II) ...............................34 
3.1 Mononucleotide repeats in introns and known microsatellite instability    
target genes.......................................................................................................34 
3.2 Search for putative microsatellite instability target genes .............................34 
3.3 Statistical analysis .......................................................................................35 
4. MLH3 MUTATION ANALYSIS (III) ............................................................................35 
4.1 Single-strand conformational polymorphism analysis ..................................35 
4.2 Radioactive polyacrylamide gel electrophoresis...........................................35 
5. EXO1 MUTATION ANALYSIS (IV) ............................................................................35 
5.1 Direct sequencing, single-strand conformational polymorphism analysis,    
and restriction analysis ......................................................................................35 
5.2 Denaturing gradient gel electrophoresis, conformation-sensitive gel 
electrophoresis, and denaturing high-performance liquid chromatography .........35 
6. MYH FOUNDER MUTATION ANALYSIS (V) ................................................................36 
6.1 Solid-phase minisequencing in detecting G382D and Y165C variants..........36 
6.2 Direct sequencing, single-strand conformational polymorphism analysis,    
and denaturing high-performance liquid chromatography ..................................36 
RESULTS ...................................................................................................................37 
1. MICROSATELLITE INSTABILITY ANALYSIS (I) ...........................................................37 
2. MUTATIONS OF MONONUCLEOTIDE REPEATS (II)......................................................37 
3. MLH3 MUTATION ANALYSIS (III) ............................................................................38 
4. EXO1 MUTATION ANALYSIS (IV) ............................................................................39 
5. MYH GERMLINE MUTATION CARRIERS (V)...............................................................39 
DISCUSSION..............................................................................................................41 
1. MICROSATELLITE MUTATIONS PRECEDE VISIBLE TUMORIGENESIS (I) ........................41 
2. MICROSATELLITE INSTABILITY TARGET GENES (II)...................................................43 
2.1 Background mutations in intronic mononucleotide repeats and mutability      
of known microsatellite instability target genes .................................................43 
2.2 Putative microsatellite instability target genes..............................................43 
3. POSSIBLE LOW-RISK ALLELES FOR COLORECTAL CANCER (III, IV) ............................45 
3.1 MLH3 (III) ..................................................................................................45 
3.2 EXO1 (IV)...................................................................................................47 
4. BIALLELIC MUTATIONS IN MYH PREDISPOSE TO MULTIPLE ADENOMAS (V) ...............49 
CONCLUSIONS AND FUTURE PROSPECTS........................................................52 
ACKNOWLEDGEMENTS........................................................................................53 
REFERENCES ...........................................................................................................55 
 
  5 
ABBREVIATIONS 
 
 
 
 
ACF   aberrant crypt foci 
APC   adenomatous polyposis coli 
ATM   ataxia-telangiectasia mutated 
BER   base excision repair 
BLM   Bloom syndrome gene 
bp   base pair 
BRCA1 and -2  breast and ovarian cancer genes 1 and 2 
CDH1   cadherin 1 
CHK2   checkpoint kinase 2 
CIMP   CpG island methylated phenotype 
CIN   chromosomal instability 
COX-2   cyclo-oxygenase-2 
CRC   colorectal cancer 
CSGE   conformation-sensitive gel electrophoresis 
CtIP CtBP-interacting protein, retinoblastoma-binding protein 8 
DAPK   death-associated protein kinase 
DCC   deleted in colorectal cancer 
DGGE   denaturing gradient gel electrophoresis 
dHPLC  denaturing high-performance liquid chromatography 
DNA   deoxyribonucleic acid 
DSB   double-strand break in DNA 
EB1   microtubule end binding 
EXO1   exonuclease 1 
FANC   Fanconi anaemia genes 
FAP   familial adenomatous polyposis 
GI   gastrointestinal 
GSK3β   glycogen synthase kinase 3β 
GSTM1 and -T1 glutathione-S transferases Mu 1 and Theta 1 
IDL   insertion/deletion loops 
HNPCC  hereditary non-polyposis colorectal cancer 
IGFII   insulin-like growth factor II   
kb   kilobase  
K-RAS   gene coding for Harvey sarcoma virus homologue, Kirsten type 
LKB1 serine/threonine protein kinase 11 
LOH   loss of heterozygosity 
LOI   loss of imprinting 
MDE   mutation detection enhancement 
MGMT  O6-methylguanine methyltransferase 
Min   multiple intestinal neoplasia 
MLH1 and -3  human mutL (E. coli) homologues 1 and 3 
MMR   mismatch repair 
  6 
MRE11 meiotic recombination protein 11 (S. cerevisiae) homologue 
MSH2, -3, -6  human mutS (E. coli) homologues 2, 3, and 6 
MSI   microsatellite instability, microsatellite-instable 
MSI-H   high microsatellite instability 
MSI-L   low microsatellite instability 
MSS   microsatellite stable 
MTH1   human MutT (E. coli) homologue 1 
MYH   human MutY (E. coli) homologue 
NAT1 and -2  N-acetyl transferases 1 and 2 
NBS1   mutated in Nijmegen breakage syndrome 
NER   nucleotide excision repair 
NF   neurofibromatosis 
OBR   leptin receptor 
OGG1   8-oxoguanine DNA glycosylase 
O6-Meg  O6-methylguanine 
8-oxoG  oxidized guanine lesion 
p   short arm of the chromosome 
p16   cyclin-dependent kinase inhibitor-2A 
PAGE   polyacrylamide gel electrophoresis 
PCNA   proliferating cell nuclear antigen 
PCR   polymerase chain reaction 
PLA2G2A  phospholipase A2, group 2A 
PMS1 and -2  postmeiotic segregation increased 1 and 2 
PPAR   peroxisome proliferative activated receptor 
PRL-3   protein-tyrosine phosphatase 3 
q   long arm of the chromosome 
RB   retinoblastoma gene 
RECQL2 and -4 RECQ protein-like 2 and 4, DNA helicases 
RNA   ribonucleic acid 
ROS   reactive oxygen species 
SMAD2 and -4 human homologues of Drosophila melanogaster Mad genes 2  
and 4 
SRC   human homologue of Rous sarcoma virus gene 
SSCP   single-strand conformational polymorphism analysis 
STK15   serine/threonine kinase 15 
TGF-β   transforming growth factor-β 
TGF-βRII  transforming growth factor-β receptor type II 
TP53   tumour protein 53 
TTDA   mutated in trichothiodystrophy 
UV   ultraviolet 
XPA-G   xeroderma pigmentosum syndrome genes 
  7 
LIST OF ORIGINAL PUBLICATIONS 
 
 
 
 
This thesis is based on the following original articles referred to in the text by Roman 
numerals I-V: 
 
 
I.  Vilkki S, Tsao JL, Loukola A, Pöyhönen M, Vierimaa O, Herva R, Aaltonen LA, 
Shibata D (2001). Extensive somatic microsatellite mutations in normal human 
tissue. Cancer Research 61, 4541-4544. 
 
II.  Vilkki S, Launonen V, Karhu A, Sistonen P, Västrik I, Aaltonen LA (2002). 
Screening for microsatellite instability target genes in colorectal cancers. Journal 
of Medical Genetics 39, 785-789. 
 
III.  Loukola A, Vilkki S, Singh J, Launonen V, Aaltonen LA (2000). Germline and 
somatic mutation analysis of MLH3 in MSI-positive colorectal cancer. American 
Journal of Pathology 157, 347-352. 
 
IV.  Jagmohan-Changur S*, Poikonen T*, Vilkki S*, Launonen V, Wikman F, Orntoft 
TF, Møller P, Vasen H, Tops C, Kolodner RD, Mecklin J-P, Järvinen H, Bevan S, 
Houlston RS, Aaltonen LA, Fodde R, Wijnen J, Karhu A (2003). EXO1 variants 
occur commonly in normal population: evidence against a role in hereditary 
nonpolyposis colorectal cancer. Cancer Research 63, 154-158. 
 
V.  Enholm S, Hienonen T, Suomalainen A, Lipton L, Tomlinson I, Kärjä V, 
Eskelinen M, Mecklin J-P, Karhu A, Järvinen HJ, Aaltonen LA (2003). 
Proportion and phenotype of MYH-associated colorectal neoplasia in a 
population-based series of Finnish colorectal cancer patients. American Journal of 
Pathology 163, 827-832. 
 
* Equal contribution 
 
 
 
 
 
 
 
 
 
 
 
  8 
ABSTRACT 
 
 
 
 
Exogenous and endogenous mutagenesis occurs continuously in DNA. To prevent 
accumulation of mutations and subsequent development of cancer, different cell 
mechanisms repair the DNA damage. Two DNA repair systems, mismatch repair (MMR) 
and base excision repair (BER), were evaluated in this study. Defects in these mutation 
repair systems are known to lead to colorectal cancer (CRC). 
 
DNA polymerases make errors in DNA replication by adding or deleting nucleotides in 
long repeat units. The normal MMR system removes these “slippages”, but if defective, 
mutations occur in the DNA. Accumulation of mutations in repeat tracts can be detected 
as microsatellite instability (MSI). Repeat sequences of numerous genes may be targets 
for frameshift mutations as a result of MMR deficiency, leading to truncated proteins. 
Mutations in MMR genes (mostly MLH1 and MSH2) have been identified as causing 
hereditary non-polyposis colorectal cancer (HNPCC), which accounts for approximately 
1-5% of all CRCs. 
 
Aerobic cell metabolism creates reactive oxygen species that damage DNA. BER is the 
primary mechanism responsible for repairing these oxidative damages. Recently, 
inherited defects in the BER system have been reported, and MYH mutations have been 
associated with colorectal neoplasia. 
 
We studied somatic microsatellite mutations in MMR-deficient cells. The phenotypically 
normal tissues of a MLH1-/- patient were evaluated, and large numbers of mutated non-
coding microsatellites were observed preceding any signs of tumour formation. To 
identify new MSI target genes, intronic and coding repeat sequences were examined in 
colorectal tumours. Comparison of mutations in intronic and exonic repeats revealed a 
novel MSI target gene, CtIP. 
 
Also studied was the role of MMR genes MLH3 and EXO1 in CRC. No MLH3 germline 
mutations were found in MSI or microsatellite-stable CRC patients, and somatic 
mutations in MSI tumours were not selected. A prominent role of MLH3 in HNPCC was 
thus excluded. Nor did EXO1 appear to predispose to HNPCC. However, the role of six 
EXO1 amino acid changes in CRC could not be excluded. Defective BER and founder 
mutations in MYH were evaluated in an unselected, population-based set of CRC 
samples, and an allele frequency of 0.006 was detected. Biallelic mutations were present 
in 0.4% of patients, and these biallelic mutation carriers seemed to have more polyps than 
patients with only one mutated allele. MYH-associated CRC was found to be as common 
as familial adenomatous polyposis-associated CRC in the Finnish population. 
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REVIEW OF THE LITERATURE 
 
 
 
 
1. SUSCEPTIBILITY TO CANCER 
 
Tumorigenesis and tumour metastasis require several genetic mutations. A single cell 
acquires mutations and loses control of the cell cycle, differentiation, and apoptosis, 
giving the mutated cell a growth advantage over normal cells. Deregulated cell 
proliferation results in the accumulation of mutated cells ultimately dependent on the 
formation of blood vessels. Tumour growth is subsequently followed by tissue invasion 
and metastasis to distant organs (Hanahan and Weinberg 2000). 
 
More than one hundred forms of cancers, which can be further divided into various 
subtypes, are known. The total number of genes and pathways involved in the formation 
of different cancers can not be specified because in each case of tumorigenesis several 
different mutated genes and pathways are involved (Hanahan and Weinberg 2000). 
However, the genes with major effects on tumour initiation can be classified into two 
groups: oncogenes and tumour suppressor genes. 
 
1.1 Oncogenes and tumour suppressor genes 
 
Proto-oncogenes are responsible for controlled cellular proliferation and differentiation. 
Because of their dominant nature, one mutated proto-oncogene allele is sufficient to lead 
to uncontrolled proliferation. Oncogenes can act by increasing the amount of gene 
product or the function by mutations, insertional mutagenesis, or gene amplification. 
Chromosomal translocations may even form proteins with new growth-enhancing 
properties (Weinberg 1994). More than one hundred oncogenes have been identified to 
date (http://www.ncbi.nlm.nih.gov/dbEST/CancerGene.html, Futreal et al. 2001). Proto-
oncogenes may function as growth factors, growth factor receptors, intracellular 
signalling transduction factors, DNA-binding nuclear proteins, and cell cycle factors. 
 
Three classes of tumour suppressor genes have been introduced: gatekeepers, caretakers 
and landscapers (Kinzler and Vogelstein 1997, 1998). Mutations of gatekeepers, such as 
proliferation-inhibiting or apoptosis-promoting genes, are essential for tumour formation. 
Deficiency of caretakers, such as DNA repair genes, leads to an accumulation of mutated 
genes, further assisting the development or progression of cancer. Landscapers modify 
the microenvironment, and thus, mutations affect the characters of a tumour. Tumour 
progression requires loss of both alleles of the tumour suppressor gene in the target 
tissue, known as Knudson’s two-hit model (Knudson 1971, 1985). A recessive effect of 
mutations may be achieved by inherited or somatic hits. After the first mutation, loss of 
heterozygosity (LOH) or epigenetic mechanisms are needed to inactivate the gene 
(Devilee et al. 2001, Tomlinson et al. 2001). 
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Recently, haploinsufficiency of tumour suppressor genes has been recognized. A study of 
the Peutz-Jeghers syndrome gene LKB1 showed that only one mutated Lkb1 allele 
resulted in gastrointestinal polyposis in mice (Rossi et al. 2002). Even though 
heterozygous mutations in tumour suppressor genes are sufficient for tumour formation, 
biallelic inactivation leads to faster tumour progression, producing more and larger 
tumours (Bai et al. 2003). 
 
1.2 Epigenetic mechanisms 
 
Not only genetic but also epigenetic changes occur during carcinogenesis. 
Hypermethylation of CpG islands, producing the CpG island methylated phenotype 
(CIMP), has been detected in colorectal cancers (CRC) (Toyota et al. 1999). DNA 
hypermethylation may act alone or in combination with genetic alterations to delete the 
function of tumour suppressor genes. Methylation of the mismatch repair gene MLH1 
promoter has been found in the majority of sporadic microsatellite-instable (MSI) colon 
cancers, leading to transcriptional repression (Herman et al. 1998, Kuismanen et al. 1999, 
Costello and Plass 2001). In addition to tumour suppressor gene silencing, expression of 
imprinted genes can be modified by aberrant DNA methylation. Loss of imprinting has 
been found for instance in the IGF2 gene. Expression of both IGF2 alleles leads to tissue 
overgrowth and tumorigenesis (Ogawa et al. 1993), and loss of IGF2 imprinting has been 
suggested as a marker of CRC risk (Cui et al. 2003). Furthermore, genes such as p16, 
DAPK, and MGMT are methylated in multiple types of tumours (Costello and Plass 
2001). 
 
Other epigenetic mechanisms include acetylation, deacetylation, and methylation of 
histones. Removal of acetyl groups from histone H3 results in an increased positive 
charge and a more condensed chromatin structure, leading to impaired transcription 
factor binding (Kuo and Allis 1998, Guschin et al. 2000). Mihaylova et al. (2003) have 
recently shown that the expression of MLH1 in mammalian cells is reduced by histone 
deacetylation under hypoxia. 
 
1.3 High- and low-penetrance genes 
 
High-penetrance or low-penetrance genes cause susceptibility to cancers. Generally, 
inherited disorders, such as hereditary non-polyposis colorectal cancer (HNPCC) or 
familial adenomatous polyposis (FAP), are caused by mutations in high-penetrance genes 
and are often inherited in an autosomal dominant fashion. Hereditary cancer syndromes 
are mostly a result of mutations in tumour suppressor genes. Mutations in high-
penetrance genes directly increase the cancer risk of the carrier. In low-penetrance cases, 
the polymorphic allele or combinations of different polymorphic alleles possibly act 
together with environmental factors, leading to increased cancer risk (de Boer 2002). 
However, high-penetrance genes may also contain low-penetrance mutations (Fraylin et 
al. 1998). 
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2. COLORECTAL CANCER 
 
As is the case for many other cancers, CRC is a multifactorial disease. Diet, life-style, 
ageing (Boyle and Leon 2002), and genetic predisposition are known to affect its 
development. Approximately 5% of the Western population suffers from CRC, and the 
disease is common in both women and men (Kinzler and Vogelstein 1996). CRC 
incidence and mortality rank among the top three cancers world-wide (http://www-
dep.iarc.fr/globocan/globocan.htm). Sporadic forms account for 65-95% of CRCs 
(Cannon-Albright et al. 1988, Houlston et al. 1992, Lichtenstein et al. 2000), and mainly 
affect persons older than 50 years (Boland et al. 1998). 
 
2.1 Non-polyposis and polyposis syndromes 
 
The inherited syndromes, consisting of non-polyposis and polyposis syndromes (Table 
1), are mainly passed down in an autosomal dominant fashion. The non-polyposis 
syndromes are HNPCC and its variants. Polyposis syndromes are further divided into 
adenomatous and hamartomatous polyposis. The former includes FAP, attenuated FAP, 
and MYH-associated polyposis. Turcot syndrome can occur with or without polyps as a 
result of mutations in the APC or mismatch repair (MMR) genes. HNPCC and MYH-
associated polyposis will be introduced in further detail in the following sections (2.1.1, 
2.1.3, 5.1, and 5.2) as the sequelae of defects in DNA repair. Rare polyposis syndromes 
with histological characteristics of hamartomatous polyps are juvenile polyposis, Peutz-
Jeghers syndrome, and Cowden syndrome. 
 
2.1.1 Hereditary non-polyposis colorectal cancer 
 
Dr. Warthin (1913) showed that CRC occurred frequently in one family. He also reported 
cancers of the endometrium and stomach in the same family. Later, inheritance of the 
syndrome was demonstrated to be autosomal dominant (Lynch et al. 1966). Tumours of 
HNPCC patients were found to contain unstable microsatellites (Aaltonen et al. 1993). 
Mutations in genes MLH1, MSH2, PMS2, and MSH6 were subsequently identified (Fishel 
et al. 1993, Leach et al. 1993, Bronner et al. 1994, Nicolaides et al. 1994, Papadopoulos 
et al. 1994, Miyaki et al. 1997). 
 
HNPCC accounts for approximately 1-5% of all CRCs (Aaltonen et al. 1998, Salovaara 
et al. 2000, Samowitz et al. 2001). HNPCC patients are about 20 years younger than 
sporadic CRC patients at diagnosis, the mean age for HNPCC onset being 44 years. In 
HNPCC patients, the progression of endoscopically flat adenomas to cancer can be rapid, 
taking only a couple of years (Boland et al. 1998). Approximately 90% of tumours in 
HNPCC patients display microsatellite instability (MSI) (Aaltonen et al. 1994, Lu et al. 
1995, Liu et al. 1996). MSI CRCs occur slightly more frequently in women than in men, 
and when compared with microsatellite-stable (MSS) colorectal tumours, they are often 
poorly differentiated and muscinous, proximally located, and have peritumoral 
lymphocyte infiltration (Ionov et al. 1993, Thibodeau et al. 1993, Boland et al. 1998, 
Elsaleh et al. 2000, Gryfe et al. 2000, Smyrk et al. 2001, Ward et al. 2001). Metastasis 
occurs less frequently in patients with MSI tumours than in patients with MSS tumours 
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Table 1. Non-polyposis (A), adenomatous polyposis (B), and hamartomatous polyposis 
(C) syndromes (Hamilton et al. 2000, Hampel and Peltomäki 2000). 
Syndrome Incidence Clinical features Genes 
responsible 
 
A. 
   
Hereditary non-polyposis 
colorectal cancer (HNPCC) 
1/1000 
(1-6% of CRCs) 
Adenomas and colon cancer, tumours of 
the endometrium, stomach, ovary, small 
bowel, biliary tract, uro-epithelium, 
kidney, central nervous system  
MLH1, MSH2, 
 MSH6, PMS2 
    
Muir-Torre syndrome 
(variant of HNPCC)
  
 Sebaceous adenomas of the face and 
scalp, keratoa-canthomas, HNPCC 
cancers, basal cell carcinomas of the skin, 
breast cancer 
MLH1, MSH2 
    
Turcot syndrome 
(variant of HNPCC) 
 Adenomas in the colon and rectum, 
colorectal tumours and glioblastomas 
MLH1, PMS2 
 
 
   
B.    
Familial adenomatous 
polyposis (FAP)  
1/8-10 000 
(<1% of CRCs) 
Hundreds to thousands of adenomatous 
polyps in the colon and rectum, colorectal 
and duodenal cancers, papillary thyroid 
carcinoma, hepatoblastoma, congenital 
hypertrophy of the retinal pigment 
epithelium, epidermoid cysts, desmoids, 
osteomas, dental anomalies 
APC   
 
    
Attenuated FAP 
(variant of FAP) 
 Dozens of polyps in the colon and 
rectum, colorectal tumours 
APC 
    
Turcot syndrome 
(variant of FAP) 
 Adenomas in the colon and rectum, 
colorectal tumours, medulloblastomas 
APC 
    
MYH-associated polyposis unknown 
(0.4-1.3% of CRCs) 
From a few to over a hundred polyps in 
the colon and rectum, colorectal cancer  
MYH 
 
 
   
C.    
Juvenile polyposis 1/100 000 Hamartomatous polyps in the stomach 
and large bowel, congenital heart defects, 
cleft lip or palate, malrotations, tumours 
of the colon, stomach, duodenum, 
pancreas  
SMAD4, BMPR1A 
    
Peutz-Jeghers syndrome 1/200 000 Hamartomatous polyps in the GI tract and 
peri-oral pigmentation, tumours of the 
colon, small intestine, stomach, pancreas, 
ovary 
LKB1 
    
Cowden syndrome 1/300 000 Hamartomatous polyps in the 
gastrointestinal tract, fibrocyctic and 
fibroadenomatous breasts, multinodular 
goiter of the thyroid and endometrial 
fibroids, skin findings, lipomas, 
macrocephaly, dolicocephaly, keratoses, 
tumours of the breast, thyroid, 
endometrium, skin, kidney, brain  
PTEN 
Recessive inheritance of the syndrome is italicized. 
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(Lothe et al. 1993, Thibodeau et al. 1993, Gryfe et al. 2000), and patients with MSI 
tumours seem to benefit from adjuvant chemotherapy (Elsaleh et al. 2000). 
 
HNPCC mutation carriers have a very high lifetime risk (>80%) of developing CRC 
(Vasen et al. 1996). Furthermore, the risk for a second primary colon cancer as well as 
endometrial, ovary, and stomach cancers is increased. Extracolonic tumours may also 
occur in the kidney, urinary tract, biliary tract, small intestine, brain, and skin (Watson 
and Lynch 1993, Aarnio et al. 1995). CRC risk has been found to be higher in male 
mutation carriers than in their female counterparts (Dunlop et al. 1997, Vasen et al. 
2001). Risk of developing CRC is also increased among MSH2 mutation carriers as 
compared with MLH1 mutation carriers (Vasen et al. 1996, 2001, Dunlop et al. 1997). 
Endometrial cancer has been shown to develop more frequently in MSH6 mutation 
carriers (Wijnen et al. 1999), and CRC caused by MSH6 mutations to have a late onset 
(>60 years) and an MSS phenotype (Kolodner et al. 1999, Wu et al. 1999b). 
 
HNPCC patients are offered regular colonoscopy. In HNPCC families, CRC incidence 
and mortality rate decreased by more than 60% when colonoscopy was carried out at 
three-year intervals. Extensive subtotal colectomy is recommended to prevent further 
colonic tumours (Järvinen et al. 2000). 
 
The clinical selection criteria to identify HNPCC families were defined in 1990 by the 
International Collaborative Group on HNPCC. Amsterdam Criteria I was revised in 1999 
to include all HNPCC-associated cancers (Vasen et al. 1991, 1999). Amsterdam Criteria 
II consists of three items: 1) at least three relatives with an HNPCC-associated cancer 
(cancers of the colorectum, endometrium, small bowel, ureter, or renal pelvis), one being 
a first-degree relative of the other two, 2) cases covering at least two generations, and 3) 
at least one cancer case diagnosed before age 50 years. In addition, FAP should be 
excluded and tumours verified by pathological examination. Advantages of the modified 
Amsterdam criteria include the possibility to use it in small families, to discover families 
with cancers other than CRC, and to test people with later onset of cancer. 
  
More than half of HNPCC families who fulfil the clinical Amsterdam criteria have 
defects in MLH1 or MSH2 (Liu et al. 1996, Wijnen et al. 1997). However, all HNPCC 
mutation carriers do not fulfil these criteria (Salovaara et al. 2000, Samowitz et al. 2001). 
Thus, testing for replication errors is recommended for patients with an early onset of 
CRC (<50 years), a suspect family history of CRC or endometrial cancer, or a history of 
multiple colorectal or endometrial cancers (Aaltonen et al. 1998). 
 
2.1.2 Familial adenomatous polyposis 
 
FAP is an autosomal dominant trait caused by mutations in the APC gene. The rectum, 
colon, and the upper gastrointestinal tract of FAP patients display hundreds or thousands 
of adenomatous polyps. At least a hundred polyps must be present to meet the clinical 
diagnosis of FAP. Without surgery, most of these patients develop colon cancer 
originating in polyps by the age of 40 years. Surveillance by sigmoidoscopy begins at the 
age of ten, and later prophylactic and total colectomies are offered (Talbot et al. 2000). 
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Depending on the location of the mutation in the gene, colonic and extracolonic features 
vary. Severe disease counted by the number of polyps is caused by mutations in the 
central region of the gene, between codons 1250 and 1464, and the most severe disease 
by mutations around codon 1300 (Nugent et al. 1994). Attenuated FAP, clinically 
diagnosed by fewer polyps at a later age, is mainly caused by mutations in exons 1-4 
(codons 1-158) (Spirio et al. 1993). The second somatic hit in APC depends on the type 
of the first mutation. The germline mutation detected between codons 1194 and 1392 
often leads to allelic loss of APC which is the second hit. If the germline mutation occurs 
outside codons 1194-1392, the second mutation will probably hit a mutation cluster 
region between codons 1286 and 1513, resulting in a truncated protein (Lamlum et al. 
1999). Desmoids in FAP patients are associated with mutations after codon 1444 
(Caspari et al. 1995), and congenital hypertrophy of the retinal pigment epithelium 
(CHRPE) between codons 463 and 1387 (Olschwang et al. 1993). One-fifth of all 
clinically diagnosed FAP patients carry no APC mutations (Hamilton et al. 2000). 
 
2.1.3 MYH-associated polyposis 
 
MYH-associated polyposis, as recently reported by Al-Tassan et al. (2002), is an 
autosomal recessive trait. Almost one-third of patients with 15-100 polyps have biallelic 
MYH mutations (Sieber et al. 2003). MYH double mutations were also found in 7% of 
patients with a clinical diagnosis of classic adenomatous polyposis but without an APC 
germline mutation (Sieber et al. 2003). Sampson et al. (2003) studied polyposis registries 
in UK and screened MYH mutations in patients selected by the following criteria: family 
history showing no vertical transmission of polyposis, at least ten colorectal adenomas, 
and no pathogenic mutation in the APC gene. Biallelic mutations were found almost in 
one-fourth of the cases. 
 
2.2 Low-penetrance genes for colorectal cancer 
 
APC polymorphisms I1307K (Laken et al. 1997) and E1317Q (Fraylin et al. 1998) have 
been reported to increase CRC risk. These APC alleles do not, however, cause the 
polyposis typical of many other APC mutations. Missense mutations in CDH1 (cadherin 
1) have also been associated with colorectal and gastric cancers (Kim et al. 2000).    
 
Various genes can modify the predisposing effect to the phenotype of a given form of 
cancer. Activation of the peroxisome proliferative activated receptor (PPAR) –γ has been 
shown to promote the development of colon tumours in heterozygous APC (APCmin/+) 
mice (Lefebvre et al. 1998). Mutated phospholipase a2 (PLA2G2A) also increased the 
number of intestinal polyps in polypotic mice (Cormier et al. 1997). The role of cyclo-
oxygenase 2 enzyme (COX-2) in CRC was recognized following the discovery of 
production of COX-2 being increased in colon cancer cells (Kargman et al. 1995). 
Furthermore, deletion of COX-2 in APC knock-out mice reduced the number and size of 
tumours in the intestine (Oshima et al. 1996). COX-2 inhibitor is also known to diminish 
polyps in FAP patients (Giardiello et al. 1993). The components of the colonic luminal 
contents, which are affected by diet, were recently demonstrated to induce COX-2 
transcription in human colon carcinoma cells (Glinghammar and Rafter 2001). 
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An association between polymorphic carcinogen metabolism genes and increased risk of 
CRC has been suggested. Some alleles of N-acetyl transferases (NAT1 and NAT2) and 
glutathione-S transferases (GSTM1 and GSTT1) that detoxify arylamines or mutagenic 
electrophiles have been proposed to have such characters (Houlston and Tomlinson 
2001). In addition, polymorphism of 5,10-methylenetetrahydrofolate reductase MTHFR 
has been shown to affect DNA methylation (Houlston and Tomlinson 2001). Up to 35% 
of all CRC cases may be due to genetic predisposition (Cannon-Albright et al. 1988, 
Houlston et al. 1992, Lichtenstein et al. 2000), but mutations of genes predisposing to 
CRC have not been found in the majority of familial CRC cases (Burt 2000). 
 
 
3. MODELS FOR COLORECTAL CANCER FORMATION 
 
3.1 From adenoma to carcinoma 
 
Approximately 40% of the population in Western countries will develop adenomas of the 
colon (DiSario et al. 1991, Lieberman and Smith 1991, Rex et al. 1991), but only a minor 
proportion develops cancer. Alterations in the Wnt signalling pathway initiate the 
formation of colon cancer in most cases. Adenomatous polyps harbour mutations or loss 
of the APC gene. Mutations in the K-ras, TP53, and TGF-β signalling pathway further 
promote tumour progression (Fearon and Vogelstein 1990) (Figure 1). Tumour 
progression of adenomas results in increasing size and dysplastic features of the polyp. A 
clear carcinoma is characterized by invasion of the basement membrane and metastasis. 
This process develops over years or decades (Muto et al. 1975). 
 
 
 
Chromosomal   5q                 12p          18q               17p 
location 
                                  SMAD2 
                      SMAD4         Other 
    APC                 K-RAS         DCC               TP53       changes 
 
              normal          dysplastic  early          inter-              late              
              epithelium         aberrant  adenoma         mediate          adenoma         carcinoma         metastasis 
                   crypt foci          adenoma 
  
 
Figure 1. Accumulation of mutations leading to the formation of CRC in a multistep 
model. Modified from Fearon and Vogelstein (1990) and Kinzler and Vogelstein (1996). 
 
 
The tumour suppressor gene product APC is known to interact with a number of proteins, 
including β-catenin (CTNNB1), glycogen synthase kinase (GSK)-3β, end binding protein 
(EB)1, axis inhibitors (axin), tubulin (TUB), the human homologue of Drosophila discs’ 
large tumour suppressor protein (hDLG) (Kinzler and Vogelstein 1996), and budding 
uninhibited by benzimidazoles (Bub) kinases (Kaplan et al. 2001). The main tumour 
promoting character of mutated APC is the insufficient degradation of β-catenin. 
Consequently, more β-catenin enters the nucleus and overactivates transcription of such 
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tumour promoting genes as c-myc, cyclin D1 (CCND1), matrilysin (MMP7), and gastrin 
(GAS) (Wong and Pignatelli 2002). APC mutations are observed in 40-80% of CRCs and 
at a similar rate in adenomas (Vogelstein et al. 1988, Leslie et al. 2002). In addition to 
APC, mutations of β-catenin in the Wnt signalling pathway are early events in CRC 
(Samowitz et al. 1999). 
 
The proto-oncogene K-RAS is involved in pathways of normal proliferation and 
differentiation, mediating signalling from growth factor receptors to signal transduction 
pathways. K-RAS mutations are displayed by 35-42% of CRCs and large adenomas. 
Moreover, lack of K-RAS mutations in small adenomas illustrates the role of this 
oncogene in providing a growth advantage for mutated cells (Vogelstein et al. 1988, 
Leslie et al. 2002). TP53, a transcription factor with tumour suppressor activity, is 
involved in the transition of adenoma to carcinoma. TP53 alterations have been shown in 
4-26% of adenomas and 50-75% of adenocarcinomas. TP53 can block the cell cycle for 
DNA repair, promote apoptosis, or further inhibit angiogenesis (Levine 1997, Leslie et al. 
2002). 
 
Different mutations in the TGF-β pathway affect transcription of genes involved in cell 
growth, differentiation, matrix production, immune surveillance, and apoptosis 
(Massague 1996). Smad proteins are also involved in this cascade. Loss of chromosome 
18q occurs in approximately 70% of CRCs and frequently also in adenomas (Vogelstein 
et al. 1988, Fearon and Vogelstein 1990). Tumour suppressor genes mutated in colon 
cancers in this area include SMAD4, SMAD2, and DCC (Fearon et al. 1990, Cho et al. 
1994, Eppert et al. 1996, Takagi et al. 1996, Fazeli et al. 1997). Moreover, mutations in 
the TGF-β type II receptor occur in several CRCs (Markowitz et al. 1995, Lu et al. 
1998), and these mutations correlate with progression of adenoma to carcinoma (Grady et 
al. 1998). 
 
The oncogene HER-2/neu is overexpressed in most CRCs, with expression correlating 
with stage of the disease (Kapitanovic et al. 1997). Mutations of the oncogenic tyrosine 
kinase SRC were reported in 12% of advanced CRCs from North America (Irby et al. 
1999), but not in CRCs from other populations (Laghi et al. 2001). In addition, increased 
expression or amplification of the gene tyrosine phosphatase PRL-3 occur in metastatic 
CRCs (Saha et al. 2001), and the protein has been shown to promote cell motility, 
invasion activity, and metastasis (Zeng et al. 2003). 
 
Some genetic alterations lead to chromosomal (CIN) or microsatellite instability (MSI) as 
accumulation of mutations increases. Most of the CRCs display CIN such as gains or 
losses of chromosomal material or alterations in chromosome number (Lengauer et al. 
1997). The molecular events underlying CIN are known to be multifactorial, and they 
include loss of telomere functions and genetic alterations in genes that control 
chromosome segregation. Recently, defects in APC, BUB kinases, TP53, STK15, RB1, 
and BRCA1 have been shown to be associated with chromosomal aberrations (Albertson 
et al. 2003). 
 
The MSI phenomenon occurs in only a small group of CRCs (12-16%) (Aaltonen et al. 
1993, Ionov et al. 1993, Thibodeau et al. 1993). MSI is currently suggested to be an 
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alternative and rapid pathway in colon cancer progression and a cause of DNA repair 
defects. Deficiency in the mismatch repair (MMR) system causes accumulation of 
mutations because polymerase errors in DNA replication are not repaired. Thus, the 
progression to carcinoma is mainly caused by mutations in short repeat tracts of MSI 
target genes (for more detail, see section 5.1.4) (Ionov et al. 1993). In these cases, 
mutations are secondary due to MMR deficiency. In the case of HNPCC, progression of a 
normal cell to carcinoma could develop over only a few years instead of taking 10-15 
years (Muto et al. 1975). Sporadic cancers with defects in the DNA repair system may 
also progress in a similar rapid way (Boland et al. 1998). 
 
3.2 Tumour clock model 
 
As described earlier, tumorigenesis is a multistep process. In the classical model of CRC 
formation, a carcinoma develops after a gatekeeper mutation and through a visible 
adenoma (Figure 2A). In HNPCC, loss of MMR leading to somatic microsatellite 
mutations and a gatekeeper mutation occurs before visible tumour formation (Shibata 
2001) (Figure 2B and C). 
 
 
         
A. 
        Normal cell 
         
B.        Loss of MMR 
 
        Gatekeeper mutation 
C.         
        Adenoma 
        
        Cancer 
 
        Microsatellite mutations before  
        a gatekeeper mutation 
  
 
Figure 2. According to the adenoma-carcinoma sequence, gatekeeper mutation and 
visible adenoma formation lead to CRC (A). Loss of MMR activity results in the 
accumulation of mutations that leads to further progression of HNPCC tumours (B and 
C) (Tsao et al. 1999, 2000). Genetic events may be deduced by microsatellite sequence 
comparisons. Modified from Shibata (2001). 
 
 
A tumour arises from a single cell after clonal expansion. Thus, mutations from that 
founder cell will be present in all tumour cells. Furthermore, each cell in the tumour 
divides and acquires new mutations. Microsatellite alterations have been used to estimate 
the number of cell divisions in phases of MSI tumorigenesis. “Slippage” occurs during 
DNA replication, leading to deletions or insertions of repeat units. A single repeat unit is 
typically changed at one time (Bhattacharyya et al. 1994, Shibata et al. 1994). Thus, 
greater numbers of microsatellite mutations around the germline allele sizes or around the 
allele sizes of the final founder cell indicate a longer time since the loss of MMR or a 
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clonal expansion, respectively. This tumour clock model was initially described by 
Shibata et al. (1996), who also proposed that MSI carcinoma may develop without 
preceding formation of a visible adenoma. Similar mutation frequencies of microsatellites 
in both adenomas and carcinomas show that an approximately equal progression period 
has occurred (Figure 2C) (Tsao et al. 1999, 2000, Kim et al. 2002). 
 
 
4. DNA REPAIR 
 
4.1 Mechanisms of DNA repair 
 
Exogenous and endogenous mutagenesis occurs continuously in DNA. DNA is damaged 
by ultraviolet irradiation, ionizing irradiation, alkylating agents, oxygen, and free 
radicals. DNA replication and recombination also produce mistakes. In the process of 
evolution, mutations are necessary, but they can also lead to disorders. Cells prevent the 
development of cancers by repairing these damaged or mutated DNA regions. 
 
Five DNA repair mechanisms with affinity for certain types of damage have been 
described. 1) O6-methylguanine (O6-MeG) DNA methyl transferase (MGMT) transfers 
the alkyl group of guanine to cysteine, thus preventing pairing of O6-MeG with thymine 
in DNA replication. 2) Double-strand break (DSB) repair is needed because breaks of 
both DNA strands are lethal if not repaired. Homologous recombination or non-
homologous end joining may be used in repairing DSB. The normal strand is used as a 
template to repair the broken area of DNA, or DNA ends are joined together without 
sequence homology from the normal DNA strand. 3) The nucleotide excision repair 
(NER) system repairs abnormal structures of DNA, including thymidine dimers after UV 
irradiation as well as chemical modifications of bases and large insertion/deletion loops 
(>15 base pairs) caused by defective MMR. 4) Base excision repair (BER) takes care of 
hydrolytic, oxidative, and alkylation damages. 5) The mismatch repair (MMR) system 
corrects mismatches and insertions/deletions and prevents heterologous DNA exchanges. 
NER, BER, and MMR mechanisms all use similar ways of repairing the damaged bases 
of DNA: splicing out the damaged region, inserting new bases, and then ligating the 
pieces (Friedberg 2003, Mohrenweiser et al. 2003). 
 
DNA damage checkpoint pathways control activation of DNA repair pathways but are 
also involved in, for example, the composition of telomeric chromatin and telomere 
length, movement of DNA repair proteins to DNA damage, and transcription of various 
genes. Cells are able to arrest the cell cycle and repair the DNA damage, but if the 
damage in DNA is too great, cells undergo apoptosis (Zhou and Elledge 2000). 
 
Recently, more than 70 genes involved in DNA damage repair or surveillance have been 
reported (Wood et al. 2001). Despite different efficient DNA repair systems, special 
DNA polymerases in the damage-tolerance mechanism may allow the DNA replication to 
continue without repairing the damage (Friedberg 2003, Mohrenweiser et al. 2003). 
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4.2 DNA repair disorders 
 
Mutations in DNA repair genes have been identified in several different human disorders, 
including cancers. Reduced expression of MGMT has been detected in tumour cells 
(Costello and Plass 2001), but the syndrome-causing germline mutations have not been 
found. Defects in the other four DNA repair mechanisms have been reported in various 
disorders (Table 2). 
 
DSB repair is affected in many disorders. In chromosome instability disorders, ATM, 
NBS1, and MRE11 genes are responsible for maintaining resistance to ionizing radiation 
(Michelson and Weinert 2000). Mutations in the RecQ family of DNA helicases (BLM, 
RECQL2, RECQL4) affect both DNA replication and homologous recombination 
(Hickson 2003). Response to the DSB (BRCA1, BRCA2, FANCs, TP53, CHK2) is 
defective, for example, at cell cycle checkpoints (Welcsh and King 2001, D'Andrea and 
Grompe 2002, Thompson and Schild 2002). Genes in the NER pathway (XPA-XPG, CSA, 
CSB, TTDA) also harbour disorder-causing mutations, and defective transcription coupled 
repair or global genomic repair has been detected in three different syndromes (de Boer 
and Hoeijmakers 2000) (Table 2). 
 
Recently, inherited defects in the BER system have been reported, and mutations of MYH 
have been associated with colorectal neoplasia (Al-Tassan et al. 2002). Moreover, 
mutations in MMR genes (mostly MLH1 and MSH2) have been found to cause hereditary 
non-polyposis colorectal cancer (HNPCC) (Fishel et al. 1993, Leach et al. 1993, Bronner 
et al. 1994, Nicolaides et al. 1994, Papadopoulos et al. 1994, Miyaki et al. 1997) (Table 
2). BER and MMR are described in detail in the following sections. 
 
 
5. COLORECTAL CANCER-CAUSING GENES IN MISMATCH REPAIR AND 
BASE EXCISION REPAIR SYSTEMS 
 
5.1 Mismatch repair mechanism 
 
The MMR system is well conserved in different organisms. Six E. coli MutS homologues 
(Msh1-6) have been found in yeast, and only MSH1 is lacking in mammals. Both in yeast 
and in human cells, the MSH2-MSH6 complex (MutSα) recognizes mispaired bases and 
single base insertion/deletion loops (IDL), while the MSH2-MSH3 complex (MutSβ) 
takes care of larger IDLs (2-4 bases) (Marsischky et al. 1996, Pochart et al. 1997) (Figure 
3). The eukaryotic MSH4-MSH5 complex is not required for MMR, but it has a role in 
meiotic recombination (Edelmann et al. 1999, Kneitz et al. 2000). 
 
Four E. coli MutL homologues have been described in both mammals and yeast: MLH1, 
PMS1, PMS2, and MLH3 (Jacob and Praz 2002). MLH1 can form complexes with other 
MutL homologues such as PMS1, PMS2, and MLH3. The MLH1-PMS2 complex 
(MutLα) interacts with mismatch recognition complexes MSH2-MSH6 and MSH2-
MSH3, repairing the mismatch or IDL in concert with other proteins (Wang et al. 1999b). 
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Table 2. Hereditary syndromes with defective DNA repair mechanisms (de Boer and 
Hoeijmakers 2000, Michelson and Weinert 2000, Welcsh and King 2001, D'Andrea and 
Grompe 2002, Thompson and Schild 2002, Hickson 2003). 
Hereditary syndrome Main clinical features Cancer 
predisposition 
Genes  
responsible 
 
Defective DSB repair 
   
Ataxia-telangiectasia Neuronal degeneration, immune 
deficiency, radiation sensitivity, sterility 
Lymphoma, leukemia, various 
solid tumours  
ATM 
    
AT-like disorder Immunodeficiency, radiosensitivity Lymphoma MRE11 
    
Nijmegen breakage 
syndrome 
Immunodeficiency, radiosensitivity Lymphoma, various tumours NBS1 
    
Bloom`s syndrome Restricted growth, sun-induced 
erythaema, type II diabetes, narrow face 
and prominent ears, male fertility  
Lymphoma, leukemia, tumours 
of the breast, gut, and skin, 
most cancer types 
BLM 
    
Werner syndrome Premature ageing, short stature, leg 
ulceration, soft-tissue calcification 
Soft-tissue and osteogenic 
sarcomas, melanoma, thyroid 
cancer 
RECQL2 
    
Rothmund-Thomson 
syndrome 
Restricted growth, skeletal abnormalities, 
skin pigmentation changes, skin atrophy 
Osteogenic sarcomas, various 
cancers 
RECQL4 
    
Fanconi anaemia Bone-marrow failure, congenital 
anomalies, dysmorphic features, growth 
retardation 
Leukemia, squamous cell 
carcinoma 
FANCA, C, 
D2, E, F, 
G, BRCA2 
    
Hereditary breast and 
ovarian cancers 
 Breast, ovarian, prostate, 
colon, and pancreatic cancers 
BRCA1, 
BRCA2 
    
Li-Fraumeni syndrome  Sarcomas, breast, lung, and 
colon cancers, brain tumours, 
leukemia 
TP53, 
CHK2 
    
Li-Fraumeni-like 
syndrome 
 Sarcomas, brain tumours, 
adrenocortical carcinoma 
TP53 
    
Defective NER    
Xeroderma pigmentosum Sensitivity to ultraviolet light, skin 
atrophy, irregular pigmentation, 
telangiectasia, keratosis 
Melanoma, basal cell 
carcinoma 
XPA-XPG 
    
Cockayne syndrome Sensitivity to many DNA-damaging 
agents, physical and mental retardation 
 CSA,  
CSB 
    
Trichothiodystrophy Sulphur-deficient brittle hair, ichthyosis, 
mental and physical retardation, sun 
sensitivity 
 XPD,  
XPB,  
TTDA 
    
Defective MMR    
Hereditary nonpolyposis 
colorectal cancer 
(HNPCC) 
 Adenomas and colon cancer, 
tumours of the endometrium, 
stomach, ovary, small bowel, 
biliary tract, uro-epithelium, 
kidney, central nervous system 
MLH1, 
MSH2, 
MSH6,  
PMS2 
 
   
Defective BER    
MYH-associated 
polyposis 
From a few to over a hundred polyps in 
the colon and rectum 
Colorectal cancer MYH 
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In some cases, the MLH1-MLH3 complex may also participate in repair of IDLs (Lipkin 
et al. 2000). The role of PMS1 in mammalian MMR remains unclear (Prolla et al. 1998, 
Räschle et al. 1999). 
 
E. coli endonuclease MutH nicks the hemimethylated DNA (Welsh et al. 1987, Hall et al. 
1999), and excision of the DNA fragment requires exonucleases such as recJ, ExoVII, 
ExoI, and ExoX (Tran et al. 1999, Burdett et al. 2001). After removal of nucleotides 
around the mismatch or IDL, the gap is filled again with the correct sequence. In humans, 
the MutH homologue has not been defined, and only one exonuclease (EXO1) has been 
found to act in MMR. In addition to MutS and MutL homologues and exonucleases, at 
least proliferating cell nuclear antigen (PCNA), DNA polymerases, replication factors, 
and helicases are needed in the process of MMR (Jacob and Praz 2002). Many as yet 
undefined genes may also have important functions in repairing mismatches or IDLs. 
 
 
 
     1 bp mismatch       short insertion/deletion loop 
 
                   A A A A A A A A                               GTGTGTGTGTG 
                   T T  T  T G T T T                                                               CACACACACAC 
          
                                 CA 
       
 
 
 
 
 
 
 
 
 
               A A A A A A A A                GTGTGTGTGTG    
               T T  T  T G T T T                CACACACACAC 
 
             
Figure 3. Mammalian DNA mismatch repair complexes: MSH2/MSH6/MLH1/PMS2 
participates in repairing mismatches and single base insertion/deletion loops and 
MSH2/MSH3/MLH1/PMS2 in repairing short insertion-deletion loops. Modified from 
Chung and Rustgi (2003). 
 
 
In addition to repair of replication mistakes or recombination, MMR proteins are 
involved in double-strand break repair (MSH2, MSH3, EXO1) and together with NER 
proteins in the transcription-coupled repair pathway (MSH2, PMS2) (Mellon and 
Champe 1996, Mellon et al. 1996, Sugawara et al. 1997, Tsubouchi and Ogawa 2000, 
Rizki and Lundblad 2001). Furthermore, the MMR system has been proven to act in 
repairing mutations caused by mutagens, such as alkylating agents or heterocyclic amines 
(Andrew et al. 1998, de Wind et al. 1998, Kawate et al. 1998, Qin et al. 1999). MLH1 
and MSH2 participate in cell cycle regulation by inducing G2/M-arrest or apoptosis in 
MSH2 
MSH2 MSH2 
MSH2 MSH3 
PMS2 
MSH6 
MSH6 
MLH1 PMS2 MLH1 
MSH3 
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response to DNA damage (Duckett et al. 1999, Hickman and Samson 1999, Toft et al. 
1999, Wu et al. 1999, Zhang et al. 1999). 
 
5.1.1 Defects in mismatch repair genes 
 
5.1.1.1 MLH1 and MSH2 
 
Most of the germline mutations of mismatch repair genes causing HNPCC are in MLH1 
(55%) (Bronner et al. 1994, Papadopoulos et al. 1994) or MSH2 (40%) (Fishel et al. 
1993, Leach et al. 1993, http://www.nfdht.nl/database/mdbchoice.htm, http://archive. 
uwcm.ac.uk/uwcm/mg/search/203983.html) (Table 3). The MLH1 mutation cluster 
locates in exons 15 and 16, but MSH2 mutations are distributed along the entire gene. In 
Finland, two MLH1 founder mutations account for the majority of HNPCC mutations 
(Nyström-Lahti et al. 1996, Aaltonen et al. 1998, Salovaara et al. 2000). Some cases of 
biallelic mutations in MMR genes in the human germline have also been recognized. 
MLH1-/- patients in two families (Ricciardone et al. 1999, Wang et al. 1999a) and one 
MSH2-/- patient (Whiteside et al. 2002) have been diagnosed with signs of 
neurofibromatosis (NF) and leukemia. 
 
In Mlh1-/- cell extracts, single base mispairs or IDLs were not corrected. Moreover, T-cell 
lymphomas and GI tumours were detected in Mlh1-/- mice (Baker et al. 1996, Edelmann 
et al. 1996). Because Mlh1-/- mice are sterile (Baker et al. 1996) and human MLH1 
interacts with the meiotic recombination protein MSH4 (Santucci-Darmanin et al. 2000), 
MLH1 protein is suggested to also be involved in meiotic recombination. 
 
Tissues in Msh2-/- mice displayed high mutation frequencies, and tumours showed MSI 
(Andrew et al. 2000). In these mice, T-cell lymphomas occurred first and GI tumours 
later (>6 months and >10 months, respectively) (Lowsky et al. 1997). Sebaceous gland 
tumours were similar to those of human patients with Muir-Torre syndrome (Kruse et al. 
1998). 
 
5.1.1.2 MSH6 and MSH3 
 
MSH6 germline mutations have also been observed in HNPCC patients (Akiyama et al. 
1997, Miyaki et al. 1997, http://www.nfdht.nl/database/mdbchoice.htm) (Table 3). In 
Msh6-/- cells, single base mismatches were not corrected, and further tumours in Msh6-/- 
mice did not display typical MSI (Edelmann et al. 1997, 2000). In these mice, T-cell and 
B-cell lymphomas occurred first, followed by GI tumours (Edelmann et al. 1997, de 
Wind et al. 1999). Tumours of the skin and endometrium were also detected (de Wind et 
al. 1999). 
 
Germline mutations of MSH3 have not been detected (Huang et al. 2001). However, in 
Msh3-/- cell extracts, dinucleotide IDLs were not repaired, and some Msh3-/- mice 
developed GI tumours at a late age. In mice, defects in Msh3 resulted in a mild mutator 
but not in a significant cancer phenotype (de Wind et al. 1999, Edelmann et al. 2000). 
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5.1.1.3 PMS1 and PMS2 
 
Only one HNPCC patient harbouring the PMS1 mutation has been found (Nicolaides et 
al. 1994, http://www.nfdht.nl/database/mdbchoice.htm) (Table 3). However, an MSH2 
germline mutation was later detected from the same patient and another affected person 
in the family. This notion confirmed that CRC was due to mutated MSH2 (Liu et al. 
2001). Thus, the role of PMS1 in HNPCC is questionable. Further, while Pms1-/--
deficient mice showed a little instability at mononucleotide repeats, they developed no 
tumours (Prolla et al. 1998). 
 
HNPCC patients with a deletion in the PMS2 gene have been reported (Nicolaides et al. 
1994, http://www.nfdht.nl/database/mdbchoice.htm) (Table 3). Mice models support the 
role of deficient Pms2 in causing a mutator phenotype. Mutation frequencies at 
mononucleotide repeat tracts in Pms2-/- tissues were lower than in Mlh1-/- tissues 
(Narayanan et al. 1997, Yao et al. 1999), and Pms2-/- mice developed lymphomas and 
sarcomas at six months of age (Baker et al. 1995, Prolla et al. 1998). A role for Pms2 in 
meiosis has also been suggested since Pms2-/- mice are sterile (Baker et al. 1995). 
 
5.1.1.4 MLH3 
 
The role of MLH3 mutations in CRC is unclear (Table 3). Germline mutations have been 
found in CRC patients, including two frame shift mutations causing a premature stop 
codon (Wu et al. 2001b, Liu et al. 2003). However, the nature of missense mutations 
remains obscure (Lipkin et al. 2001, Wu et al. 2001b, Hienonen et al. 2003, Liu et al. 
2003). The importance of Mlh3 in the MMR system has recently been studied. 
Overexpression of truncated Mlh3 induced MSI in mammalian cells (Lipkin et al. 2000), 
but MSI was not detectable in Mlh3-/- fibroblasts (Lipkin et al. 2002). In addition to 
MMR, the role of Mlh3 in meiosis has been demonstrated in Mlh3-/- mice (Lipkin et al. 
2002). 
 
5.1.1.5 EXO1 
 
In humans, a double-stranded DNA-specific 5’ to 3’ exonuclease EXOI was found to 
bind MSH2, MSH3, and MLH1 and was thus suggested to act in the MMR system 
(Schmutte et al. 1998, 2001, Tishkoff et al. 1998). EXO1 germline mutations have been 
sought in CRC patients: 14 mutations were found, including one splice site mutation (Wu 
et al. 2001a). The data from a yeast study indicated that Exo1 defects lead to 
accumulation of base substitutions and frameshift mutations in mononucleotide runs 
(Tishkoff et al. 1997). In mice, Exo1 has been shown to function both in the MMR 
system and in meiosis. Exo1-deficient mice harboured unstable mononucleotide repeats 
and lymphoma (Wei et al. 2003). 
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Table 3. MMR genes affecting the phenotype of yeast and mammals. Only germline 
mutations in humans are taken into account. Modified from Lipkin et al. (2000) and 
Peltomäki (2001). 
DNA mismatch 
repair gene 
Chromosomal 
location 
Yeast Mammals 
  MSI Mouse tumours Human cancers 
MLH1 3p21-23 ++ Lymphoma (T-cell) 
GI tumours 
CRC 
MSH2 2p21 ++ Lymphoma (T-cell) 
GI and skin cancer 
CRC, sebaceous gland 
tumours and internal 
malignancies 
PMS2 (yeast Pms1) 7p22 ++ Lymphomas and sarcomas 
(myxoid and fibroid 
sarcoma, leiomyosarcoma) 
CRC 
MSH6 2p21 + Lymphoma (B- and T-cell) 
GI, uterine, and skin 
tumours 
CRC, tumours of the 
endometrium 
MLH3 14q24.3 + - CRC? 
EXO1 1q42-43 + Lymphomas CRC? 
MSH3 5q11-12 + Late GI tumours - 
PMS1 (yeast Mlh2) 2q31-33 - - - 
++ Severe MSI phenotype in yeast 
+ Less intense MSI phenotype 
- Not detected 
? More data needed 
GI Gastrointestinal 
Mammalian PMS2 is most closely related to yeast Pms1. 
Mammalian PMS1 is most closely related to yeast Mlh2, which is not associated with MSI. 
Mice heterozygous for these mutations do not display increased tumour formation. 
 
 
5.1.2 Inactivation of mismatch repair genes 
 
In HNPCC, the inactivation of MMR genes involves the first inherited mutation, and the 
second allele is later somatically mutated in the epithelial cells of the target tissue. This 
second change, a somatic deletion, a point mutation, or methylation of the promoter, can 
inactivate the wild-type allele and further act as a driving force for tumour development. 
In MLH1 and MSH2 mutation carriers, LOH is detected in approximately 30% and 10% 
of tumours, respectively (Hemminki et al. 1994, Potocnik et al. 2001). In MLH1 mutation 
carriers, 46% of gene inactivation is caused by promoter hypermethylation (Kuismanen et 
al. 2000). Point mutations in MLH1 mutation carriers are rare when compared with 
MSH2 mutation carriers (Yuen et al. 2002). In contrast to HNPCC tumours, 78% of 
sporadic MSI CRCs were found to have reduced MLH1 expression mainly due to 
promoter methylation (Kane et al. 1997, Kuismanen et al. 2000). Approximately 6-15% 
of tumours showed reduced MSH2 expression, and LOH or mutation in MSH2 was 
detected (Kuismanen et al. 2000, Cunningham et al. 2001). 
 
5.1.3 Microsatellite instability 
 
Microsatellites consist of six or fewer nucleotides, and form repeat tracts of up to 100 
base pairs (Levinson and Gutman 1987). These repetitive elements are targets for 
replication mistakes made by DNA polymerases. “Slippage” of the polymerase leads to 
insertions or deletions of repeat units. If MMR genes are defective, these DNA changes 
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are not repaired, and microsatellite mutations accumulate. The lengths of microsatellite 
repeats were found to be unstable in unselected and familial CRCs (Aaltonen et al. 1993, 
Ionov et al. 1993, Thibodeau et al. 1993, Peltomäki et al. 1993). The Bethesda panel of 
five microsatellite markers has been proposed for the detection of microsatellite 
instability (MSI) (Boland et al. 1998). Three dinucleotide repeat markers (D2S123, 
D5S346, D17S250) and two mononucleotide repeat markers (BAT25, BAT26) are used 
to distinquish MSI-L (low) and MSI-H (high) instability from microsatellite-stable (MSS) 
samples. At least two markers with instability confirm MSI-H tumours, and one marker 
showing instability defines MSI-L tumours (Boland et al. 1998). BAT26 alone is 
sufficient to distinguish MSI-H tumours, when compared to corresponding normal tissues 
(Hoang et al. 1997, Aaltonen et al. 1998). 
 
MSI-H tumours have a lower frequency of K-ras, TP53, and β-catenin mutations and less 
LOH on chromosomes 5q, 17p, and 18q than MSS tumours (Jass et al. 1999). Jass et al. 
(1999) showed that MSI-L tumours could be distinguished from MSS tumours by a 
higher frequency of K-ras mutations and a lower frequency of 5q LOH. Recently, Laiho 
et al. (2002) suggested that both MSS and MSI-L tumours could be classified by MSS 
status. K-RAS mutations, MGMT and MLH1 promoter methylation, and LOH at APC, 
TP53 or SMAD4 loci did not differ between MSS and MSI-L tumours (Laiho et al. 2002). 
 
5.1.3.1 Microsatellite instability target genes 
 
Repeat sequences of numerous genes may be targets for frameshift mutations as a result 
of MMR deficiency. These sequences are mostly mononucleotide repeats. The frameshift 
mutations lead to truncated proteins with impaired function, possibly contributing to 
tumour development (Table 4). The first MSI target genes proposed in HNPCC were 
TGFβ-RII (Markowitz et al. 1995), IGFIIR (Souza et al. 1996), and BAX (Rampino et al. 
1997). Since then, many other genes with mutations in repeat tracts have been reported to 
be results of MMR defects. In 2002, a total of 110 publications contained 245 coding and 
non-coding mononucleotide microsatellite analyses of 177 genes in MSI colorectal, 
gastric, or endometrial cancers (Woerner et al. 2003). MSI target genes encode proteins 
destined for such different roles as signal transduction, apoptosis, DNA repair, 
transcriptional regulation, protein translocation and modification, and immune 
surveillance (Woerner et al. 2003). The somatic mutation frequencies of proposed MSI 
target genes vary from <10% to >60%, with the exception of TGFβ-RII, which is mutated 
in approximately 90% (Markowitz et al. 1995, Parsons et al. 1995) of MSI CRCs (Table 
4). 
 
The character of microsatellites affects the mutation rate. Differences in length of the 
repeat unit, base composition of the repeat, number of repeat units, possible interruptions 
in the tract, and type of flanking sequences cause variable mutation frequencies of repeats 
(Boyer et al. 2002). Thus, different models have been provided to distinguish real target 
genes from bystander or background mutations. The nature of real target genes can be 
confirmed by high mutation frequency and by in vitro or in vivo functional studies 
(Boland et al. 1998, Duval et al. 2001). Other criteria have been discussed and 
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Table 4. Mutations of coding mononucleotide repeats in MSI CRCs (at least 9% 
mutation frequency reported in the first publication).  
Gene Coding 
repeat 
Mut 
% 
Function Reference 
Β2-microglobulin A5 14 Immune surveillance Bicknell et al. 1996 
PTEN A6 x2 19 Cell cycle Guanti et al. 2000 
AXIN-2 A6 x2, G7, C6 24 Wnt signalling Liu et al. 2000 
FAS T7 10 Proapoptotic factor Yamamoto et al. 2000 
CYSLT1 A8 9 Inflammatory response Mori et al. 2001 
TPRDI A8 9 Putative extracellular matrix component Mori et al. 2001 
Actin depolymerizing 
factor 
T8 10 Acts in actin depolymerization Mori et al. 2001 
CDC25C A8 11 Triggers entry into mitosis Park et al. 2002 
Protein-tyrosine-
phosphatase D1 
A8 12 Intracellular signalling Mori et al. 2001 
APAF-1 A8 13 Proapoptotic factor Yamamoto et al. 2000 
BCL-10 A8 13 Proapoptotic factor Yamamoto et al. 2000 
Coagulation factor 
VIII:C 
A8 15 Coagulation factor Mori et al. 2001 
BDH A8 16 Maintains cytoskeletal structure Shin et al. 2003 
RACK7/PRKCBP1 A8 19 Intracellular signalling Park et al. 2002 
GARE T8 20 Endocrine signalling Laghi et al. 2002 
hG4-1 A8 21 Cell cycle Mori et al. 2001 
MSH3 A8 39 DNA repair Malkhosyan et al. 1996 
ACTRII A8 58 Growth factor signalling Mori et al. 2001 
PRRG1 C8 9 Homology to coagulation factors Mori et al. 2001 
IGFIIR G8 9 Growth factor signalling Souza et al. 1996 
SEX G8 14 Growth factor signalling Mori et al. 2001 
TFE3 C8 23 Transcription factor Potocnik et al. 2003 
RGS12 C8 29 Regulator of G protein signalling Potocnik et al. 2003 
MSH6 C8 30 DNA repair Malkhosyan et al. 1996 
TEF4 C8 32 Transcription enhancer factor Potocnik et al. 2003 
TCF1 C8 32 Transcription factor Potocnik et al. 2003 
BAX G8 51 Promotes apoptosis Rampino et al. 1997 
ERCC5 A9 10 DNA repair Park et al. 2002 
CHK1 A9 10 Cell cycle Bertoni et al. 1999 
MCT T9 11 Intracellular transport Mori et al. 2001 
RECQL1 A9 12 DNA repair Park et al. 2002 
Exportin t T9 14 Translation Mori et al. 2001 
CBF2 A9 16 Transcription factor Park et al. 2002 
BLM A9 18 Response to DNA damage Calin et al. 1998 
RHAMM A9 19 Cell motility Duval et al. 2001 
GRK4/GPRK2L A9 21 Intracellular signalling Park et al. 2002 
NADH-UOB T9 28 Cell metabolism Mori et al. 2001 
WISP-3 A9 31 Growth factor Thorstensen et al. 2001 
RAD50 A9 33 Response to DNA damage Kim et al. 2001 
GRB-14 A9 34 Growth factor signalling Duval et al. 2001 
RIZ A9, A8 37 Cell cycle Chadwick et al. 2000 
TCF-4 A9 39 Transcription factor Duval et al. 1999 
SEC63 A9, A10 49 ER membrane protein Mori et al. 2001 
SLC4A3 C9 33 Anion exchanger Woerner et al. 2001 
SLC23AI C9 45 Nucleobase transporter Woerner et al. 2001 
GART A10 24 Cell metabolism Woerner et al. 2001 
MBD4 A10 26 DNA repair Riccio et al. 1999 
DNAPK/PRKDC A10 33 DNA repair and recombination Park et al. 2002 
MAC30X A10 33 Cytosceletal functions Woerner et al. 2001 
PRKDC A10 35 Intracellular signalling Woerner et al. 2001 
OGT T10 40 Cell metabolism Woerner et al. 2001 
AIM2 A10 48 Inflammatory response Mori et al. 2001 
Caspase-5 A10 62 Proapoptotic factor Schwartz et al. 1999 
TGF-βRII A10 82 Growth factor signalling Markowitz et al. 1995 
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questioned. First, a role for candidate target genes in cellular pathways was speculated to 
be important. However, this role cannot necessarily be explained since its cellular 
mechanism may as yet be unknown. Second, inactivation of both alleles has been 
emphasized. Inactivation of the target gene may occur either by biallelic alteration of the 
repeat or by imprinting (Boland et al. 1998, Perucho et al. 1999, Duval et al. 2001, Duval 
and Hamelin 2002). Haploinsufficiency or the dominant negative effect of MSI target 
genes (Liu et al. 2000) explains the importance of only one mutated allele. 
 
To cover all types of genes with mutations in repeat tracts, Duval and Hamelin (2002) 
divided MSI target genes into four groups. First, normal expression of “survivor” genes is 
needed in the cell, and thus mutations will be avoided. Second, the “hibernator” genes do 
not have important functions in affected cells, and their expression is down-regulated. 
Mutations in these genes are not selected for, and the mutation rate would show up as 
background mutations. Third, mutations in “co-operator” genes could have importance in 
combination with other mutations in the same pathway. Variable mutation frequencies of 
these genes can be obtained. Fourth, mutations of “transformator” genes provide a 
positive growth advantage for MSI cells and have the highest mutation frequencies. 
 
Most of the MSI target gene mutations accumulate in cells, eventually leading to 
uncontrolled growth. In MSI tumour progression, TGFβ-RII inactivation was often found 
to be the second event after MMR gene mutation, and in some cases, MSH3 was the third 
target of mutation. The MMR phenotype is modified by the mutated MSH3, which 
further increases mutations in nucleotide repeats (Grady et al. 1998, Duval et al. 2001). 
 
5.2 Base excision repair mechanism 
 
Reactive oxygen species (ROS) mainly produced by aerobic cell metabolism but also by 
radiation, macrophages, and chemical agents damages DNA (Aruoma et al. 1989, Ames 
et al. 1993, Henle and Linn 1997). BER is used in the repair of methylated or deaminated 
DNA bases and is also proposed to be the primary mechanism responsible for the repair 
of oxidative damage in DNA. In addition to mutagenesis and further carcinogenesis, 
oxidized DNA bases are known to play a role in ageing and in neurological disorders 
(Ames et al. 1993). 
 
Like many other DNA repair systems, the BER system is well conserved in different 
organisms. DNA glycosylases identify specific types of base damage. There are over ten 
known DNA glycosylases (Mohrenweiser et al. 2003) which hydrolyse the N-glycosidic 
bond between the base and sugar-phosphate backbone, thus releasing the damaged base. 
An apurinic/apyrimidinic (AP) endonuclease nicks the sugar-phosphate backbone at the 
position of the missing base. Exonucleases remove some nucleotides from the DNA 
strand and the DNA polymerase fills the gap. In all, over thirty different genes involved 
in BER have been described (Mohrenweiser et al. 2003). 
 
Repair of oxidized guanine lesions is an example of BER system function. Oxidized 
guanine is highly mutagenic and one of the main causes for spontaneous mutations. In 
DNA replication, an adenine residue is more frequently added opposite to an oxidized 
guanine lesion 8-oxoG than is a cysteine residue. This leads to GC→TA transversions 
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(Cooke et al. 2003). E. coli glycosylases mutY and mutM have been reported to repair 
oxidized guanine lesions 8-oxoG in DNA (Cabrera et al. 1988, Michaels et al. 1992, 
Nghiem et al. 1998). Human homologues of mutM (OGG1) (Roldan-Arjona et al. 1997) 
and mutY (MYH) (Slupska et al. 1996) have also been identified. The role of OGG1 is to 
remove the 8-oxoG opposite to a cysteine residue from the DNA (Figure 4). All damage 
is not immediately repaired, but after replication, MYH removes an adenine residue 
across from 8-oxoG (Boldogh et al. 2001). Polymerases insert a cysteine residue in place 
of the removed adenine, and OGG1 can then repair the lesion. The role of MutT (MTH1) 
is to hydrolyse the oxidized dGTPs to unusable monophosphates, thus preventing the 
formation of a mutated DNA strand (Maki and Sekiguchi 1992, Sakumi et al. 1993). 
 
Proteins other than MYH, OGG1, and MTH1 have also been detected with repair activity 
against 8-oxoG in vitro. For example, the mammalian alkylpurine DNA glycosylase 
(Bessho et al. 1993) and the human NER system (Reardon et al. 1997, Le Page 2000, 
Tuo 2001) have been reported to have such functions. The human Nei-like glycosylase 1 
(NEIL1) has also been shown to preferentially remove the 8-oxoG opposite to an adenine 
(Hazra et al. 2002). 
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Figure 4. Oxidative damage results in the formation of a 8-hydroxyguanine (GO), which 
can be removed by the OGG1 protein. During replication GO mispairs with an adenine 
residue, which can be removed by MYH. Modified from Slupska et al. (1996). 
 
 
5.2.1 Defects in base excision repair genes 
 
Mutations and polymorphisms of OGG1 on chromosome 3p26 have been detected in the 
lung, kidney (Chevillard et al. 1998), ovarian and endometrial tumours, and one leukemia 
cell line (Pieretti et al. 2001, Hyun et al. 2002). Recently, it was also suggested that 
polymorphism of OGG1 may alter the impact of environmental factors on colon cancer 
development (Kim et al. 2003). Studies of animal models showed that mutation 
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frequency increased slightly in some tissues of Ogg1-/- mice, but no tumours were 
detected. This indicates the role of various enzymes in repairing 8-oxoGs (Klungland et 
al. 1999, Minowa et al. 2000). Increased expression of MTH1 on chromosome 7p22 and 
accumulation of 8-oxoG have been detected in human brain tumours (Okamoto et al. 
1996, Iida et al. 2001); however, the role of MTH1 in CRC has not been shown. Mice 
models lacking the Mth1 gene harbour spontaneous carcinogenesis in the lung, liver, and 
stomach (Tsuzuki et al. 2001). 
 
5.2.1.1 MYH 
 
Mutations in MYH on chromosome 1p32-p34 were recently detected in CRC cases. Al-
Tassan et al. (2002) showed that multiple somatic transversions in the APC gene were the 
result of MYH deficiency in patients with colorectal adenomas and carcinomas. Two 
amino acid variants of MYH were identified from three affected siblings, and compound 
heterozygosity of mutations revealed a recessive trait. Recent studies have reported more 
biallelic germline mutations in MYH and described multiple adenomas in these patients 
(Jones et al. 2002, Halford et al. 2003, Sieber et al. 2003). 
 
Functional evidence of mutated MYH was represented by a greater than 80% reduction 
of enzyme function. MYH mutations almost totally reduced adenine removal from G:A 
substrates in E. coli (Al-Tassan et al. 2002). The mutations were suggested to occur in 
conserved areas of glycosylase, probably affecting catalytic activities and the recognition 
of mismatches. 
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AIMS OF THE STUDY 
 
 
 
 
Evaluation of somatic microsatellite mutations caused by mismatch repair deficiency: 
 
1. Evaluation of normal tissues in an MLH1-/- patient. 
2. Detection of the mutation frequencies of mononucleotide repeats in colorectal 
cancers. 
 
 
Evaluation of germline mutations in DNA repair genes and their association with 
colorectal cancers: 
 
3. Identification of the mutation status of mismatch repair genes MLH3 and EXO1. 
4. Evaluation of the frequency of MYH founder mutations and further 
characterization of the phenotype of mutation carriers. 
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MATERIALS AND METHODS 
 
 
 
 
1. PATIENTS AND DNA SAMPLES 
 
1.1 MLH1-/- patient (I) 
 
A four-year-old girl with café au lait spots, glioma, and strong family history of HNPCC 
(both parents mutation carriers) was suspected of MLH1 deficiency. The patient died of 
intracranial haemorrhage. Tissue samples of the brain, kidney, heart, liver, bladder, 
lymph node, and glioma were obtained at autopsy. The samples were received from Oulu 
University Hospital. The study was approved by the Ethics committee of the Department 
of Medical Genetics, University of Helsinki. 
 
1.2 Colorectal carcinoma patients (II-V) 
 
A set of 1042 unselected Finnish CRC samples was the basis for CRC Studies II-V 
(Table 5). This set has been described in detail elsewhere (Aaltonen et al. 1998, 
Salovaara et al. 2000). The diagnoses of cancers and the possible connection to identified 
HNPCC families were obtained from the Finnish Cancer Registry, the Finnish HNPCC 
Registry and the Finnish Polyposis Registry. The study was approved by the Ethics 
committee of the Department of Medical Genetics, University of Helsinki. 
 
1.2.1 Searching for microsatellite instability target genes (II) 
 
A panel of 93 MSI colorectal tumours was used to study intronic mononucleotide repeats 
and known MSI target genes IGFIIR and BLM. Thirty MSI colorectal tumours were used 
in screening for mutations of eight possible MSI target genes. An additional 79 MSI 
tumour samples were used to sequence the repeat tract of CtIP. A summary of all CRC 
samples used in Studies II-V is presented in Table 5. 
 
1.2.2 MLH3 analysis (III) 
 
Normal DNA of 46 MSI and six MSS CRC patients was used for MLH3 germline 
analysis. Of these patients, 43 were selected because of at least one first- or second-
degree relative with cancer and three for their young age. Six patients whose MSS 
colorectal tumours showed 14q deletions were also used for MLH3 analysis. These 
patients had at least one first-degree relative with CRC. Ninety-three MSI tumours were 
screened for repeats of MLH3 (Table 5). 
 
1.2.3 EXO1 analysis (IV) 
 
The following three groups of Finnish CRC patients were selected for EXO1 germline 
mutation analysis (Table 5): 1) Normal DNA from 19 CRC patients (18 families), 17 of 
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which had at least one first-degree relative, were sequenced for EXO1 mutations. 
Tumours of eight patients were MSI with no germline MLH1 or MSH2 mutation found. 
2) Samples from 111 MSS or MSI-L CRC patients with a first-degree relative with CRC, 
67 MSS CRC patients with early age of onset (≤50 years) and unknown family history, 
and 122 CRC patients aged over 50 years and without family history of CRC were used 
in EXO1 single-strand conformational polymorphism (SSCP) analysis. 3) Samples from 
80 patients with familial CRC and 3 patients with early onset of cancer (≤50 years) were 
studied for the IVS12-1 variant. 
 
CRC patients from the Netherlands, Norway, the UK, and Denmark were included in 
Study IV (Table 5). Of the 116 Dutch and 39 Norwegian families (1 sample/family), 55 
fulfilled the revised Amsterdam criteria, 68 were suspected HNPCC families, and 32 
were identified with late onset of CRC. MSH2, MLH1, or MSH6 mutations were 
excluded. Four hundred and eighteen CRC cases from the UK were diagnosed before 
patients reached the age of 56 years. Danish CRC samples were from 97 suspected 
HNPCC patients. 
 
1.2.4 MYH analysis (V) 
 
Analysis of MYH mutations was based on a set of 1042 unselected DNA samples from 
CRC patients (Aaltonen et al. 1998, Salovaara et al. 2000). MSI was discovered in 130 
tumours, and MLH1 or MSH2 germline mutations were detected in 29 samples (Aaltonen 
et al. 1998, Salovaara et al. 2000, unpublished data). Normal DNA from 1003 patients 
was available for the MYH study (Table 5). 
 
1.3 Control individuals (I, III-V) 
 
Colon harbouring a normal MMR mechanism was used as control tissue in Study I. The 
Finnish Red Cross of Helsinki provided control DNA samples from anonymous blood 
donors in Studies I, III, IV, and V. In addition to Finnish controls, anonymous controls or 
spouses of CRC patients from the Netherlands, Norway, the UK, and Denmark were used 
in Study IV. 
 
1.4 DNA extraction (I-V) 
 
DNA from fresh frozen tumours and blood samples was extracted using standard 
procedures (Lahiri and Nurnberger 1991). Histological analysis of tumour samples was 
used to confirm that a maximum amount of tumour tissue was used for DNA extraction. 
DNA from the brain, kidney, heart, lymph node, colon, and bladder epithelium (Study I) 
obtained at autopsy was extracted according to Shibata et al. (1996). 
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Table 5. CRC samples used in Studies II-V. 
Number 
of 
samples 
Family history of cancer Age of 
onset 
MSI status of 
tumour 
Mutation 
analysis 
Study Gene 
93 - - MSI PAGE II MSI targets, 
intronic 
repeats 
30+79 - - MSI Direct sequencing II MSI targets 
43 At least one first- or 
second-degree relative 
with cancer 
- MSI  SSCP III MLH3 
3 - Mean  
40 y 
MSI SSCP III MLH3 
6 At least one first-degree 
relative with CRC 
- MSS SSCP III MLH3 
93 - - MSI PAGE III MLH3, OBR 
19 17 had at least one first-
degree relative with CRC 
45-84 y MSI or MSS  
 
Direct sequencing IV EXO1 
111 At least one first-degree  
relative with CRC 
- MSS or MSI-L 
 
SSCP IV EXO1 
67 - ≤50 y MSS SSCP IV EXO1 
122 No family history >50 y Sporadic SSCP IV EXO1 
80 Familial CRC - MSI or MSS Restriction 
analysis 
IV EXO1 
3 - ≤50 y - Restriction 
analysis 
IV EXO1 
55 Revised Amsterdam 
criteria 
- - DGGE IV EXO1 
68 Suspected HNPCC 
families 
- - DGGE IV EXO1 
32 - Late - DGGE IV EXO1 
418 Family history of CRC <56 y  CSGE IV EXO1 
97 Suspected HNPCC 
families 
- - dHPLC IV EXO1 
1003 - - MSI or MSS Solid phase 
minisequencing 
V MYH 
- Unknown data 
 
 
2. STUDY OF THE MLH1-/- PATIENT (I) 
 
2.1 MLH1 mutation 1 analysis 
 
Mutation 1 of MLH1 is an in-frame 165 base pair (bp) deletion of exon 16. This 3.5 kb 
genomic deletion in MLH1 was detected by polymerase chain reaction (PCR) and agarose 
gel electrophoresis. Three primers (Nyström-Lahti et al. 1995) were used to identify the 
634 bp mutated allele (primers 1+2) and the 475 bp normal allele (primers 2+3). With 
primers 1 and 2, the normal allele is about 4 kb and thus not produced. 
 
2.2 Microsatellite analysis 
 
DNA from the heart, kidney, lymph node, and bladder epithelium was diluted for 
radioactive microsatellite analysis with markers DXS556, DXS1060, and DXS453. PCR 
reactions were labelled by incorporating (α-33P)dCTP (NEN) in the synthesized strands, 
and products were analysed by polyacrylamide gel electrophoresis (PAGE) (Tsao et al. 
  34 
2000). Between 42 and 56 molecules were genotyped for each tissue sample at each 
locus. 
 
Allele sizes of markers DXS556, DXS1060, and DXS453 in different tissues were 
compared with allele sizes in normal tissue. Variances of allele size distributions under 
the stepwise mutation model were considered to represent the numbers of mutations at 
the loci (Tsao et al. 2000). The number of cell divisions equals the number of mutations 
per mutation rate. Mutations from already mutated alleles back to normal allele size 
cannot be excluded or estimated in this quantitative analysis. 
 
TGFβRII primers were used to detect frameshifts in the A10 repeat of the tumour 
suppressor gene (Loukola et al. 1999) in normal lymphocytes of the MLH1-/- patient and 
controls. DNA samples from the MLH1-/- patient were diluted to the point at which PCR 
amplification detected alleles from a single cell. 
 
 
3. SEARCH FOR MICROSATELLITE INSTABILITY TARGET GENES (II)  
 
3.1 Mononucleotide repeats in introns and known microsatellite instability target genes 
 
Background mutations of 14 intronic (A/T)6-9 and (G/C)6-9 repeats were studied by 
radioactive PCRs and PAGE (Table 5). The set of 93 MSI colorectal tumours was used to 
detect deletions or insertions of mononucleotide repeats. Radioactive (α-32P)dCTP 
(Amersham Pharmacia Biotech) PCR products were run on 6% polyacrylamide gels. 
After exposure, all aberrant bands were sequenced and somatic mutation was confirmed 
by analysing the corresponding normal DNA. The known MSI target genes IGFIIR and 
BLM were screened for mutations in the G8 and A9 mononucleotide repeats, 
respectively, using the same method. 
 
3.2 Search for putative microsatellite instability target genes 
 
Bioinformatic tools were used in the search for novel candidate MSI target genes. 
Mononucleotide repeats of eight base pairs or more were sought from coding sequences 
added to the GenBank since 1997. Eighty-three keywords related to cancer were 
combined with found repeat sequences and their Medline records, resulting in 251 
sequences. The other search was based on sequence homology of repeat-containing genes 
to 34 known tumour suppressor or CRC-related genes. This effort resulted in 841 hits. A 
small group of candidate MSI target genes was selected according to abstracts (Study II, 
Table 2). 
 
Thirty MSI CRCs were used in sequencing the repeat area of eight possible MSI target 
genes. The primer sequences and PCR conditions are described in Study II (Table 2). An 
additional 79 MSI samples were used to sequence the repeat tract of CtIP. The nature of 
somatic mutations was confirmed in the presence of normal DNA. 
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3.3 Statistical analysis 
 
Logistic regression analysis was used in estimating the correlation of the independence 
and significance of mutation frequency with repeat length in the intron. χ2 test was used 
for other analyses. p<0.05 was considered statistically significant. 
 
 
4. MLH3 MUTATION ANALYSIS (III) 
 
4.1 Single-strand conformational polymorphism analysis 
 
Single-strand conformational polymorphism (SSCP) analysis was performed with normal 
DNA of 52 CRC patients (Table 5). MLH3 was amplified in 24 fragments (Study III, 
Table 1). The PCR products were denaturated and run on a 0.6x mutation detection 
enhancement (MDE) gel (FMC BioProducts). MDE gels were silver-stained according to 
standard procedure, and all aberrant bands were sequenced. 
 
4.2 Radioactive polyacrylamide gel electrophoresis 
 
Somatic mutation analysis was carried out by radioactive PAGE analysis as described 
earlier (Section 3.1). Ninety-three MSI tumours (Table 5) were screened for coding A6-
A9 mononucleotide repeats of MLH3 (6xA6, 1xA8, 1xA9) (Study III, Table 2) and non-
coding A8 and A9 repeats of OBR. 
 
  
5. EXO1 MUTATION ANALYSIS (IV) 
 
5.1 Direct sequencing, single-strand conformational polymorphism analysis, and 
restriction analysis 
 
Nineteen CRC patients from 18 families (Table 5) and 20 controls were sequenced for 14 
exons of EXO1 using an ABI 3100 DNA sequencer (AB). Eight candidate mutations 
detected by Wu et al. (2001a) were screened from 300 Finnish CRC patients and 373 
controls by SSCP (method described earlier in Section 4.1). Detected variants were 
confirmed by direct sequencing. The NlaIV restriction enzyme (New England Biolabs) 
was used according to manufacturer’s instructions to screen the ninth mutation, 
truncating variant IVS12-1 (G/C), from 83 Finnish CRC patients and 504 controls. 
 
5.2 Denaturing gradient gel electrophoresis, conformation-sensitive gel electrophoresis, 
and denaturing high-performance liquid chromatography 
 
Denaturing gradient gel electrophoresis (DGGE) (Fodde et al. 1992) was used to screen 
the EXO1 gene in 155 Dutch/Norwegian families. Twenty-four primer pairs were used 
according to the study by Wu et al. (2001a). PCR products were run on a 9% 
polyacrylamide gel with a denaturing gradient of 30-60% urea/formamide. 
Conformation-sensitive gel electrophoresis (CSGE) (Ganguly et al. 1993) was used to 
detect three candidate mutations of exon 11 (Ser610Gly, Pro640Ser, Pro640Ala) in the 
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UK cohort. Primers were described by Wu et al. (2001a). PCR products were run on a 
6% polyacrylamide gel containing 15% formamide and 10% ethylene glycol. The DGGE 
and CSGE gels were stained with ethidium bromide, and bands were detected in UV 
light. Danish samples and controls were screened by denaturing high-performance liquid 
chromatography (dHPLC) for the three (Ser610Gly, Pro640Ser, Pro640Ala) exon 11 
mutations. dHPLC heteroduplex analysis was carried out on the Transgenomic Wave 
genetic analyser (Transgenomics). All variants detected by the various screening methods 
were sequenced to identify the mutation. Furthermore, EXO1 sequences of Homo 
sapiens, Mus musculus, Drosophila melanogaster, S. cerevisiae, and S. pompe were 
aligned using the Clustal W (1.82) multiple sequence alignment program (Thompson et 
al. 1994). 
 
 
6. MYH FOUNDER MUTATION ANALYSIS (V) 
 
6.1 Solid-phase minisequencing in detecting G382D and Y165C variants  
 
Solid-phase minisequencing in streptavidin-coated wells (Labsystems) was carried out to 
detect Caucasian G382D and Y165C (Al-Tassan et al. 2002) MYH variants in CRC 
patients. Genomic DNA from 16-22 patients was pooled for PCR, for a total of 52 pools 
covering DNA from 1003 patients (Table 5). Detection primers were hybridized next to 
the analysed nucleotide in PCR products, and bound specific H3-labelled nucleotides 
(Amersham) described the amount of normal or mutant alleles (Syvänen et al. 1993, 
Suomalainen and Syvänen 2000). PCR and minisequencing were repeated for positive 
pools. Double-positive pools were divided into smaller pools containing ten DNA 
samples each. After two positive results from small pools, reactions with individual DNA 
were carried out. χ2 test was used for examining MYH mutation distribution between 
CRC patients and controls. p<0.05 was considered statistically significant. 
 
6.2 Direct sequencing, single-strand conformational polymorphism analysis, and 
denaturing high-performance liquid chromatography 
 
To search for additional MYH defects, patients with only one mutated allele in the 
germline were sequenced for all exons in both normal and tumour DNA with primer 
sequences as described earlier by Al-Tassan et al. (2002). Mutation cluster (nt 1286-
1513) of the APC gene was examined in tumours of MYH mutation carriers. Exons 15A 
to 15L were screened by fluorescent SSCP and dHPLC analyses. For more detail, see 
Study V. 
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RESULTS 
 
 
 
 
1. MICROSATELLITE INSTABILITY ANALYSIS (I) 
 
A patient with glioma, a neurofibromatosis phenotype, and a HNPCC family history was 
diagnosed with a homozygous 165 bp deletion in MLH1 exon 16. Both parents harboured 
the heterozygous mutation. 
 
DNA from the heart, kidney, lymph node, and bladder epithelium was diluted to amplify 
alleles from a single cell. DNA from the brain was too degraded for analysis. CA-repeats 
detected by markers DXS556, DXS1060, and DXS453 showed allele size variation in 
different autopsy tissues. From seven to 15 mutant alleles were detected, when between 
42 and 56 molecules were genotyped for each tissue sample at each locus (Study I, Table 
1). Somatic mutations were present in 15-32% of alleles in different autopsy tissues. 
Control tissue, colon harbouring a normal MMR mechanism, showed only one mutant 
allele (marker DXS556). Thus, less than 5% of mutant alleles were detected by the three 
microsatellite markers. The allele sizes, presented as a number of CA-repeats, varied 
from 24 to 31 as detected by the unimodal marker DXS556, from 18 to 26 by bimodal 
marker DXS1060, and from 16 to 28 by bimodal marker DXS453 (Study I, Figure 3A). 
Microsatellite allele frequency distributions were identical between tissues. Variances of 
allele frequency distributions ranged between 0.26 and 1.4: in the heart 0.36-1.0, in the 
kidney 0.26-0.59, in lymph nodes 0.32-0.95, and in bladder epithelium 0.38-1.4 (Study I, 
Table I). In other words, approximately equal numbers of mutations seemed to occur in 
different tissues of the MLH1-/- patient. A total of 0.26-1.4 mutations per locus per cell 
had occurred, assuming that variances of microsatellite mutation frequency distributions 
are proportional to numbers of microsatellite mutations (Tsao et al. 2000). Numbers of 
cell divisions in tissues (= number of mutations/mutation rate) were calculated by using 
the microsatellite mutation rate 5x10-3 per cell division (Bhattacharyya et al. 1994, 
Shibata et al. 1994). Thus, MLH1-/- cells had divided approximately 52-280 times. 
 
An A10 mononucleotide repeat of TGFβRII was studied in DNA samples aquired from 
peripheral lymphocytes of the MLH1-/- patient. Diluted DNA showed amplification in 
134 PCRs out of a total of 221. One base pair deletion of the repeat was found in one 
TGFβRII PCR, but also in one out of 96 control PCRs from blood donor DNA. 
 
 
2. MUTATIONS OF MONONUCLEOTIDE REPEATS (II) 
 
The mutation frequencies of 14 intronic (A/T)6-9 and (G/C)6-9 repeats are summarized 
in Study II (Table 1). Mutation frequencies varied between 0% and 5.7%. By logistic 
regression analysis, the length of G/C and A/T intronic mononucleotide repeats correlated 
positively with the number of mutations (p=0.0020 and p=0.0012, respectively).  
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The known MSI target genes IGFIIR (coding G8 repeat) and BLM (coding A9 repeat) 
showed mutations in nine out of 92 (9.8%) and 18 out of 93 cases (19.4%), respectively. 
Mutation frequencies in BLM (19.4%) and intronic A/T9 repeats (4.3-5.7%) differed 
significantly (p≤0.001), and when results of earlier studies (Souza et al. 1996, Ouyang et 
al. 1997, Calin et al. 2000) were combined with findings made here, the IGFIIR mutation 
rate (28/216=13%) was also found to differ significantly from the intronic G/C8 mutation 
rate (2.5%) (p≤0.01). 
 
A search for putative MSI target genes using keywords related to cancer and tumour 
suppressors or CRC-related sequence homology, resulted in 251 and 841 hits, 
respectively. The eight genes BCL10, PTP-BAS, CtIP, BAI1, p73, GIOT-2, PAIP, and 
RIP3 were screened for mutations in exonic mononucleotide repeats (Study II, Table 2). 
CtIP had mutations in 22.9% of MSI tumours (25/109). No mutations were detected in 
the other seven genes. Comparison of CtIP with intronic A/T9 mutations (4.3-5.7%) 
revealed a significant difference (p≤0.001). Combined data of CtIP mutations from this 
study and Ikenoue et al. (2001) (25/122=20.5%) were also compared with intronic A9 
mutations, and the significant difference remained (p≤0.001). No mutations in other 
exonic 5-6 bp mononucleotide repeats of CtIP were found. Tumours of CtIP mutation 
carriers did not differ in their histology from other MSI CRCs. In addition, age 
distributions at diagnosis and tumour site distributions were similar. CtIP mutations were 
observed in similar numbers in men (14/49) and women (11/60). 
 
 
3. MLH3 MUTATION ANALYSIS (III) 
 
No MLH3 germline mutations were found in 52 CRC patients by SSCP. Two exonic 
variants, G1258A (Val420Ile) and G4377A (Gln1421Gln), were detected both in CRC 
patients (allele frequencies 2.9% and 46%, respectively) and healthy controls (allele 
frequencies 2.7% and 49%, respectively). A third exonic change, A1234G (Lys412Glu, 
allele frequency 3.8%), was detected as a result of sequencing somatic mutations in 
tumours; it was also found in controls (allele frequency 1.1%). One intronic variant, 
IVS9+55 G to C (allele frequency 2.9%), was revealed by SSCP, and another intronic 
change, IVS8+66 A to G (allele frequency 50%), was uncovered by sequencing SSCP 
variants. 
 
Somatic deletions of MLH3 mononucleotide repeats were found in eight out of 93 cases 
(allele frequency 8.6%) when studying eight mononucleotide repeats (6xA6, 1xA8, 
1xA9) in coding regions. One mutation was found in an A8 repeat (nt 2128), and seven 
were detected in an A9 repeat (nt 1861), resulting in a premature stop codon. The OBR 
gene was used as a control in the screening of somatic mutations in intronic 
mononucleotide repeats: three deletions in an A8 repeat (allele frequency 3.2%) and three 
deletions in an A9 repeat (allele frequency 3.2%) were present in the same set of 93 MSI 
tumours. 
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4. EXO1 MUTATION ANALYSIS (IV) 
 
A summary of all EXO1 variants found in Finnish, Dutch, Norwegian, British, and 
Danish data sets and in the study by Wu et al. (2001a) is presented in Study IV (Table 1). 
Comparing EXO1 variants in 19 Finnish CRC patients and 20 cancer-free controls 
revealed that a Pro640Ser change was the only remaining putative mutation. To further 
evaluate nine mutations reported by Wu et al. (2001a), 970 familial and sporadic CRC 
cases (Table 5) and 1007 controls were studied by SSCP, DGGE, CSGE, dHPLC, and 
restriction analyses. Five of the mutations (Ser610Gly, Pro640Ser, Pro640Ala, truncating 
variant IVS12-1 G/C, Gly759Glu) presented in CRC cases in Wu et al. (2001a) were 
found both in CRC patients (allele frequencies 0.3%, 0.6%, 0.4%, 0.2%, and 0.8%, 
respectively) and controls (allele frequencies 0.07%, 0.5%, 0.3%, 0.2%, and 1.9%, 
respectively) in the present study. 
 
Four mutations found by Wu et al. (2001a), Val27Ala, Glu109Lys, Leu410Arg, and 
Pro770Leu, were not detected in controls. Neither were three of these mutations 
(Val27Ala, Glu109Lys, Pro770Leu) found in CRC probands of this study. Only one 
Leu410Arg mutation was found in CRC patient (allele frequency 0.2%). LOH as a 
second hit in the tumour was not detected in exon 11 variants (Ser610Gly, Pro640Ser, 
Gly670Gly) from seven Finnish CRC patients, when comparing alleles in tumours and 
normal tissues by sequence intensities. 
 
In addition, five new unpublished variants were detected: one in controls, three in CRC 
patients only, and one in both controls and CRC patients. A G/A change in place of 
truncating variant IVS12-1 G/C was found in a Finnish control. An Ala827Val change 
was found in a Dutch CRC patient and control. New CRC patient variants not present in 
controls were Ala137Ser, Phe438Cys, and a silent Asp661Asp variant. These were 
detected in Dutch/Norwegian patients. Combined data from this study and from Wu et al. 
(2001a) identify six amino acid changes detected in only CRC probands (Val27Ala, 
Glu109Lys, Ala137Ser, Leu410Arg, Phe438Cys, Pro770Leu). According to the EXO1 
sequence alignment of Homo sapiens, Mus musculus, Drosophila melanogaster, S. 
cerevisiae, and S. pompe, all six changes affected non-conserved amino acids of the 
EXO1 protein. 
 
 
5. MYH GERMLINE MUTATION CARRIERS (V) 
 
Three Y165C/G382C compound heterozygotes and one G382D homozygous mutation 
carrier were found when searching for MYH variants in 1003 samples (0.4%) from a 
population-based series of 1042 Finnish CRC patients. Furthermore, five patients 
harboured either mutation Y165C or G382C (Study V, Table 2). These patients with only 
one mutant allele showed no other mutations of the gene in the germline or in the tumour 
as evidenced by sequencing. Allele frequency of mutated MYH was 0.006 (13/2006) 
when the Y165C mutation was present in four alleles (0.002) and the G382D mutation in 
nine alleles (0.004). MYH founder mutations were not found among the 424 cancer-free 
controls, and the difference between CRC patients and controls reached significance 
(p<0.025). 
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The phenotype of mutation carriers displayed some variation, but four patients with two 
mutated alleles had five to one hundred polyps, and patients with only one mutated allele 
had either none, one, or more than six polyps (Study V, Table 2). No particular type of 
malignancy was observed in first-degree relatives of the nine CRC patients with MYH 
mutations. Eight out of nine mutation carriers had at least one first-degree relative with 
some form of cancer, and of these, two probands had three and five first-degree relatives 
suffering from cancer (Study V, Table 2). Tumours other than CRC were not available 
for this study. 
 
Of the set of 1042 Finnish CRC cases, 35 (3.4%) were shown to have a genetic 
predisposition to cancer (Study V, Table 3). Mutations in five genes (MLH1, MSH2, 
APC, ALK3, MYH) have been detected. According to the Finnish Polyposis Registry, four 
FAP cases were diagnosed during the CRC collection from May 1994 to July 1998. 
During this same period, four patients with MYH double mutations were detected. Thus, 
the frequency of APC and MYH mutations seems to be equal in the Finnish population. 
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DISCUSSION 
 
 
 
 
1. MICROSATELLITE MUTATIONS PRECEDE VISIBLE TUMORIGENESIS 
(I) 
 
The MLH1-/- (exon 16 del) female patient died at the age of four years of a haemorrhage 
caused by glioma. Café au lait spots and axillary freckles were also detected. The 
phenotype of the MLH1-/- patient was similar to other cases described earlier (Gly67Trp, 
Arg226Stop) (Ricciardone et al. 1999, Wang et al. 1999a). In two families, five patients 
were found with café au lait spots, dermal neurofibromas, pseudoarthrosis, and axillary 
freckles common in neurofibromatosis type 1 (Ricciardone et al. 1999, Wang et al. 
1999a). In four patients, lymphomas or leukemias were diagnosed before the age of three. 
In one patient, leukemia was diagnosed at the age of six. However, haematological 
malignancies were not diagnosed in the patient of Study I. In addition to homozygous 
MLH1 mutation carriers, a woman with compound heterozygous missense mutations was 
reported by Hackman et al. (1997). This patient was diagnosed with breast cancer at the 
age of 35, and the mild phenotype was suggested to be the result of remaining activity of 
the MLH1 allele. Recently, a patient with a homozygous MSH2 mutation was also 
reported. This patient had MLH1-/--like symptoms: café au lait spots and leukemia 
(Whiteside et al. 2002). Gliomas, usually astrocytomas or glioblastomas, may associate 
with HNPCC (Hamilton et al. 2000). However, glioma of the MLH1-/- patient is not 
necessarily a HNPCC tumour. DNA from the brain or glioma was not available for Study 
I. 
 
MMR-deficient patients and mice have similar phenotypes of haematological 
malignancy, and thus, MMR-deficient mice models are important for studies of MMR-
deficient patients. Mlh1-/- mice have been found to develop early invasive lymphomas, 
and the majority of mice surviving more than half a year developed adenomas and 
adenocarcinomas of the intestine (Edelmann et al. 1996, Prolla et al. 1998). The 
phenotype of Msh2-/- mice was similar to that of Mlh1-/- mice (de Wind et al. 1995, 
Reitmair et al. 1995, 1996). 
 
A rate of 2 x 10-7 mutations per locus per cell division has been estimated in normal 
somatic cells (Loeb 2001). Similar mutation rates have also been observed in MSS 
sporadic cancers (Wang et al. 2002). Deficiencies in DNA repair do, however, lead to an 
increased rate of somatic mutations, and in MMR-deficient cells, base substitutions and 
short mononucleotide repeat deletions are increased approximately 100-fold (Narayanan 
et al. 1997, Andrew et al. 2000). CA-repeats at microsatellite loci have been shown to 
mutate even more (Bhattacharyya et al. 1994, Shibata et al. 1994). In this study, 
microsatellites in different tissues (heart, kidney, lymph node, bladder epithelium) of the 
MLH1-/- patient mutated between 0.26 and 1.4 times per microsatellite locus per cell. This 
reveals a great mutation frequency compared with MMR-deficient tissue culture studies 
(approximately 5 x 10-3 mutations/locus/cell) (Bhattacharyya et al. 1994, Shibata et al. 
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1994). Consistent with the findings of this MLH1-/- patient study, phenotypically normal 
cells from Mlh1-/- mice (Edelmann et al. 1996) and humans (Wang et al. 1999a) have 
shown genetic instability. 
 
Despite the large numbers of non-coding microsatellite mutations in the MLH1-/- patient, 
differences in mutations between tissues were not detected. Differences could possibly 
have occurred over time due to the character of the several tissues and cell types used. 
However, because the patient died at the age of four years, there may have been 
insufficient time for mutations to accumulate. A molecular tumour clock analysis 
assuming the stepwise mutation model has shown that the majority of somatic 
microsatellite mutations accumulate before tumour formation (Tsao et al. 2000). Thus, 
the time for accumulation of mutations before a gatekeeper mutation could be long. 
Patterns of microsatellite mutations in CA-repeats have shown that loss of MMR occurs 
on average six years before tumour removal (Tsao et al. 2000), explaining the absence of 
tumours in the four-year-old MLH1-/- patient.  When tissues of the MLH1-/- patient and 
MMR-deficient mice (Pms2) (Tsao et al. 1997) were compared, only at one year of age 
did the MMR-deficient mice show greater variances of microsatellite allele sizes in the 
intestine than the four-year-old MLH1-/- patient in any tissue. Furthermore, MLH1-/- 
human cancer (Tsao et al. 2000) showed higher variance of microsatellite allele 
frequency distribution than phenotypically normal tissues of the MLH1-/- patient. Taken 
together, these data indicate the importance of time in the accumulation of mutations and 
the potential usefulness of the molecular tumour clock model in the determination of 
occult changes. 
 
Different studies have shown that lack of MMR leads to haematological malignancy. In 
both MLH1-/- and MSH2-/- patients, downstream mutations could occur in genes such as 
NF1, causing haematological malignancies (Ricciardone et al. 1999). Various other target 
genes could also mutate in MMR-deficient patients, and tumours would likely progress 
over time. However, the role of possible mutations in the formation of tumours before 
loss of MMR and their absence in MMR-deficient patients remains to be elucidated 
(Huang et al. 1996, Miyaki et al. 1999, Kim et al. 2002). 
 
In this study, the putative mutability of repeat tracts in lymphocytes was also examined. 
TGFβ-RII is a gene mutated in approximately 90% of MSI CRCs (Markowitz et al. 1995, 
Parsons et al. 1995), but the mutation frequency of a coding A10 repeat in blood 
lymphocytes of the MLH1-/- patient was not increased when compared with the cancer-
free control. This result is consistent with a recent study in which several microsatellite 
markers displayed no instabilities in lymphocyte DNA of an MMR-deficient patient 
(Whiteside et al. 2002). Mutations due to MMR deficiency occur during DNA 
replication. Thus, if lymphocytes divide infrequently, mutations in repeat tracts must be 
rare. Furthermore, mononucleotide repeats have been shown to mutate less frequently 
than microsatellite loci with CA repeats (Bhattacharyya et al. 1994, Shibata et al. 1994). 
In conclusion, in this study, large numbers of mutated non-coding microsatellites were 
shown to occur in phenotypically normal tissues of an MLH1-/- patient before any signs of 
tumour formation. 
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2. MICROSATELLITE INSTABILITY TARGET GENES (II) 
 
2.1 Background mutations in intronic mononucleotide repeats and mutability of known 
microsatellite instability target genes 
 
Intronic mononucleotide repeats with different nucleotides and lengths have not been 
adequately studied for mutation rates. Only 25 non-coding microsatellites in 22 different 
human genes were presented in 33 publications in 2002 (Woerner et al. 2003). Here, the 
length of eight A/T6-9 and six G/C6-9 repeats correlated positively with the mutation rate 
of these repeats. The results also demonstrated that mutations occur sporadically in 
sequence repeats due to MMR deficiency, but unless the mutations are selected for, the 
mutation frequency appears to be low (<6%). Indeed, according to Suzuki et al. (2002), 
non-coding nucleotide repeat tracts (A8-9, G7-9) displayed few mutations (mutation 
frequencies 0-6.7%) in MMR-deficient tumours. However, intronic G8 repeats mutated 
more frequently than A8 repeats when a total of 29 repeats were examined (Zhang et al. 
2001). Because monomorphic G8 and G9 repeats were difficult to find, only one non-
coding repeat of each length was analysed. Comparisons of mutability between A and G 
repeats would have required more data on analysed repeats. However, independent tracts 
did mutate at different frequencies, similar to earlier reports (Zhang et al. 2001, Suzuki et 
al. 2002). Sequence or chromatin structure around the tract could possibly explain these 
differences (Zhang et al. 2001). 
 
In the previously described MSI target genes BLM (A9) and IGFIIR (G8), low mutation 
rates of 16-18% and 9.3-22% (Souza et al. 1996, Calin et al. 1998, 2000), respectively, 
were confirmed in this study by similar mutation rates (19.4% and 9.8%). Mutation 
frequencies of repeats in BLM and IGFIIR were significantly different from 
corresponding intronic repeats, demonstrating selection for these mutations in coding 
regions. The mutation rate, the biallelic inactivation, and functional studies in vitro have 
confirmed the MSI target gene character of IGFIIR. Mutated IGFIIR is not able to bind 
its ligand IGFII, disabling further activation of proteins involved in the control of cellular 
proliferation and apoptosis (Motyka et al. 2000). Germline mutations in the BLM gene 
have been detected in patients suffering from a hereditary cancer syndrome called 
Bloom´s syndrome, and heterozygous mutations of BLM have been reported to slightly 
increase CRC risk (Gruber et al. 2002). Mutations in the BLM gene that affect DNA 
unwinding lead, for example, to abnormal DNA replication and an elevated level of 
homologous recombination (Hickson 2003). 
 
2.2 Putative microsatellite instability target genes 
 
Mononucleotide repeats of eight candidate MSI target genes BCL10 (T7), PTP-BAS (A8), 
CtIP (A9), BAI1 (C7), P73 (C6), GIOT-2 (T7), PAIP (T6), RIP3 (A6) were studied in 
MSI CRCs. The mutation frequency of 22.9% in the CtIP gene suggests that CtIP could 
be a putative novel MSI target gene. No mutations were detected in the other seven 
genes. Comparing the results of CtIP with A9/T9 intronic repeats used in this study 
indicated the potential of CtIP in MSI tumorigenesis. Mutation frequencies of CtIP and 
corresponding intronic repeats differed significantly. This suggests that CtIP mutations 
are advantageous for the cell and thus are selected for. The mutation rate of the A9 repeat 
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in CtIP was even higher than in the MSI target gene BLM (19.4%). Comparison of CtIP 
with previously proposed MSI target genes containing mutable A9 repeats (mutation 
frequencies 10-49%) suggests that CtIP is a reasonable target for MSI. However, CtIP-
mutated patients could not be distinguished from other MSI CRC patients by 
histopathology of the tumour, sex of the patient, age at tumour occurrence, or site of the 
tumour. Many different cellular pathways may be affected by MSI simultaneously, and 
thus, the phenotype of a tumour is the result of accumulated mutations. 
 
While we propose that CtIP is a target for mutations in mononucleotide repeats caused by 
MMR deficiency, Li et al. (2000) showed that the DNA damage response may occur 
through CtIP. A large complex acting in DNA damage consists of DNA repair proteins 
(MSH2, MSH6, MLH1, ATM, BLM), RAD50-MRE11-NBS1 protein complex, DNA 
replication factor C, and BRCA1 (Wang et al. 2000). From this complex, at least MSH6 
(Malkhosyan et al. 1996), ATM (Ejima et al. 2000), BLM (Calin et al. 1998), and RAD50 
(Kim et al. 2001) genes are targets for MSI. Defects in response to DNA damage caused 
by mutations in these genes lead to increased genomic instability and tumour progression. 
ATM is known to phosphorylate proteins involved in cell cycle progression and DNA 
damage repair. For example, phosphorylation of p53 activates the protein and leads to 
transcription of p21 and GADD45 (Banin et al. 1998, Canman et al. 1998). Interestingly, 
after ionizing radiation, ATM also phosphorylates CtIP at serine residues (Ser664, 
Ser745). This leads to dissociation of the CtIP-CtBP complex from BRCA1 and further to 
BRCA1-dependent transcription of the GADD45 gene (Li et al. 2000). As in the case of 
mutated serine residues (Li et al. 2000), truncated CtIP might also prevent GADD45 
transcription and the response to DNA damage. The DNA damage activated pathway 
mediated by ATM is a factor in the progression of MSI CRC. 
 
CtIP binds Rb, a key regulator of G1/S transition of the cell cycle, and Rb-mediated 
repression of transcription can be relayed through CtIP. E2F binds to the target gene 
promoter and CtIP interacts with Rb/p130/E2F complex and CtBP, allowing CtBP to 
mediate repression (Meloni et al. 1999). Thus, lack of CtIP could lead to transcription of 
genes encoding proteins for cell cycle progression or DNA replication. 
 
CtIP may belong to the group of “co-operator” genes described by Duval and Hamelin 
(2002). Mutations of different “co-operator” genes show variable mutation frequencies, 
but the same pathway may be affected in all cases. Not only genes with high mutation 
frequencies but also rarely mutated repeat tracts in different CRCs might have an 
important task in MSI tumorigenesis. Inactivated proteins lead to deficiency of the 
pathway, and thus, low-frequency mutations could also be considered as relevant 
(Perucho 2003). If the question of mutation frequency in repeats is difficult, also the 
evidence of biallelic mutations is controversial. Biallelic mutations in CtIP were not 
detected. However, a biallelic mutation alone does not necessarily prove the impact of the 
phenotype. Recently, haploinsufficiency or a dominant negative effect of MSI target gene 
products has also been discussed (Perucho 2003). According to Perucho (2003), only 
functional evidence is adequate to prove the authenticity of novel MSI target genes. 
Indeed, functional studies confirming the nature of CtIP as a true MSI target gene are 
warranted. 
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3. POSSIBLE LOW-RISK ALLELES FOR COLORECTAL CANCER (III, IV) 
 
The efficiency and accuracy of DNA repair can be affected by polymorphisms or defects 
in many genes. Proteins that do not directly act in DNA repair but interact with repair 
proteins or are mediators in a signal pathway may have an influence on repair processes. 
Not only loss of function but also mild reductions in DNA repair genes may cause cancer 
predisposition. Association studies are used in detecting low-penetrance genes. The 
frequencies of gene variants are compared among patients and controls, and the ethnicity 
of cases must be taken into consideration. Combinations of variants in different genes 
may also affect the phenotype. Furthermore, environmental factors can have a great 
impact on the phenotype of low-penetrance mutation carriers. The age-structure of cases 
and controls is relevant in, for example, determining probable exposure to carcinogens 
(Houlston and Tomlinson 2000, Mohrenweiser et al. 2003). 
 
Mutations in at least MLH1, MSH2, MSH6, and PMS2 seem to cause CRC. Several novel 
human genes involved in the MMR system have recently been cloned and studied in 
HNPCC. According to Studies III and IV, germline mutations in MLH3 or EXO1 do not 
predispose affected individuals to HNPCC. In general, studies of sequence variants in 
these genes have failed to demonstrate their importance in CRC, but the role of some of 
the variants or low-penetrance mutations could neither be confirmed nor excluded 
(Lipkin et al. 2001, Wu et al. 2001a, 2001b, Hienonen et al. 2003, Liu et al. 2003). 
 
3.1 MLH3 (III) 
 
In yeast, Mlh3 interacts with Mlh1 and is involved in the repair of insertions or deletions 
longer than 2 bp (Flores-Rozas and Kolodner 1998). Overexpression of mutated Mlh3 has 
been shown to lead to MSI in mouse cell lines (Lipkin et al. 2000), but the role of the 
MLH1-MLH3 complex in humans needs to be studied further. Indeed, we did not find 
germline mutations in 46 samples from CRC patients with MSI tumours or in six CRC 
patients harbouring 14q deletions in MSS tumours. The three variants G1258A 
(Val420Ile), A1234G (Lys412Glu), and G4377A (Gln1421Gln) in exons 1 and 11, 
detected in CRC samples, were also found in controls at a similar frequency. These 
results suggest that the germline mutations in MLH3 are likely not involved in HNPCC. 
Furthermore, the importance of MLH3 in MMR can be questioned. Yeast and mouse 
studies have demonstrated that Mlh3 does not have a significant role in MMR (Harfe and 
Jinks-Robertson 2000, Lipkin et al. 2002). Mlh3 has been shown to be associated with 
Msh4 in mammalian meiotic cells, supporting its role in meiotic recombination 
(Santucci-Darmanin et al. 2002). 
 
Somatic mutations of MLH3 in 93 MSI tumours occurred in eight A8-A9 repeats. 
However, while the mutation frequency (8.6%) remains at a level similar to that of 
intronic A8 and A9 control repeats (6.5%), somatic MLH3 mutations seem not to be 
selected for. Thus, they do not play a key role in the formation of tumours. Akiyama et 
al. (2001) and Lipkin et al. (2001) also detected somatic frameshift mutations in MLH3 
mononucleotide repeats (14.8% and 25%, respectively). In contrast to the present study, 
Lipkin et al. (2001) found biallelic inactivation containing both A8 and A9 repeat 
  46 
mutations in four of the six tumours. Lipkin et al. (2001) also reported two stop codon 
causing mutations in 14q LOH MSS tumours. 
 
In summary, the present study together with Lipkin et al. (2001) found no MLH3 
germline mutations in CRC patients. Hienonen et al. (2003) detected a missense variant, 
not present in cancer-free controls. Wu et al. (2001b) and Liu et al. (2003), by contrast, 
showed both missense and frameshift mutations. Wu et al. (2001b) reported 10 MLH3 
germline mutations from 39 HNPCC patients as well as 288 HNPCC suspects, one being 
a frameshift 2578delA. Liu et al. (2003) found the frameshift mutation 885delG twice in 
the same family and 11 missense mutations in 70 suspected familial CRC cases (Table 6). 
Most tumours with MLH3 mutations were MSI-negative (Wu et al. 2001b, Liu et al. 
2003), similar to animal studies (Harfe and Jinks-Robertson 2000, Lipkin et al. 2002). 
Polymorphisms seemed to vary between studies and possibly between populations (Liu et 
al. 2003). Furthermore, different mutation screening methods (SSCP, DGGE, dHPLC) 
were used in these five studies. In conclusion, some of the mutated MLH3 genes may 
have a minor effect on CRC, possibly with some other low-risk alleles (Liu et al. 2003). 
 
 
Table 6. At least 33 different germline variants have been reported in the coding 
sequence of MLH3. 
Nucleotide Amino acid substitution Reference 
C70G Gln24Glu Wu et al. 2001  
T344C* Phe74Leu* Lipkin et al. 2001 
T561C* Tyr149Tyr* Lipkin et al. 2001 
A691C Lys231Gln Liu et al. 2003 
885delG Termination 37 bp downstream Liu et al. 2003 
C1111T* Asn333Asn* Lipkin et al. 2001 
G1153C* Asp385His* Hienonen et al. 2003 
T1168A* Phe390Ile* Hienonen et al. 2003 
A1234G* Lys412Glu* Study III, Liu et al. 2003 
G1258A* Val420Ile* Study III, Hienonen et al. 2003 
A1496G Asn499Ser Wu et al. 2001 
G1870C* Glu624Gln* Wu et al. 2001, Hienonen et al. 2003, Liu et al. 2003 
C1939T Arg647Cys Wu et al. 2001  
G2221T Val741Phe Liu et al. 2003 
A2425G Met809Val Hienonen et al. 2003 
A2449G Ser817Gly Wu et al. 2001 
C2531T* Pro844Leu* Liu et al. 2003 
2578delA Termination 49 bp downstream Wu et al. 2001  
G2590A* Glu841Asn* Lipkin et al. 2001 
G2797T Gly933Cys Liu et al. 2003 
C2825T* Thr942Ile* Hienonen et al. 2003, Liu et al. 2003 
C2838A* Ser947Ser* Liu et al. 2003 
T2896C* Ser966Pro* Hienonen et al. 2003, Liu et al. 2003 
G2911A Val971Ile Liu et al. 2003 
G2941A Gly981Ser Wu et al. 2001 
A3020G Asn1007Ser Wu et al. 2001  
C3315A* Asp1105Glu* Hienonen et al. 2003 
T3826C Trp1276Arg Liu et al. 2003 
G4180A Ala1394Thr Wu et al. 2001 
G4351A Glu1451Lys Wu et al. 2001, Liu et al. 2003 
G4356C* Gln1414His* Lipkin et al. 2001 
G4362A* Lys1416Lys* Lipkin et al. 2001 
G4377A* Gln1421Gln* Study III 
* Polymorphisms  
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3.2 EXO1 (IV) 
 
Wu et al. (2001a) presented strong evidence for the truncating variant of EXO1 (IVS12-1 
G/C) as a predisposing mutation for CRC. In Study IV, this variant was found in a Dutch 
CRC sample. The CRC patient fulfilled the Amsterdam criteria and had an MSI-L 
colorectal tumour. The patient’s brother, who also suffered from CRC, harboured the 
same truncating mutation. Despite this, the change was considered polymorphic because 
it was also found in three Dutch controls (Table 7). More polymorphism in the place of a 
truncating variant was detected when a Finnish control revealed a IVS12-1 G/A change. 
RNA from this patient was unavailable, and the splicing effect could not be confirmed. 
Thus, the splicing variant reported by Wu et al. (2001a) in the family with HNPCC 
appears to be a polymorphism. In addition to the truncating variant, four other candidate 
mutations (Ser610Gly, Pro640Ser, Pro640Ala, Gly759Glu) of the nine reported by Wu et 
al. (2001a) were detected in both CRC samples and controls of this study, and deemed 
polymorphisms. 
 
The role of the four variants Val27Ala, 
Glu109Lys, Leu410Arg, and Pro770Leu 
in CRC reported by Wu et al. (2001a) 
could not be confirmed in the present 
study. Three of the mutations were not 
detected in either CRC samples or 
controls. The fourth variant Leu410Arg 
was found in a Dutch/Norwegian 
putative HNPCC patient but could not be 
detected in controls (Table 7). Moreover, 
the same CRC patient carried a MSH2 
missense mutation of unknown 
pathogenicity, suggesting that mutations 
in different genes together could cause a 
more severe phenotype than either 
mutation alone. Indeed, although 
mutations in S. cerevisiae Exo1 cause a 
mutator phenotype (Tishkoff et al. 
1997), Exo1 mutant yeast models have 
shown that Exo1 mutations together with 
defects in Mlh1, Pms1, Msh2, Msh3, and 
Pol30 cause stronger mutator phenotypes 
than single mutants (Amin et al. 2001).  
 
Four new EXO1 variants (Ala137Ser, 
Phe438Cys, Asp661Asp, Ala827Val) 
were uncovered in addition to the  
Table 7. Germline variants have been 
reported in the coding sequence of EXO1 
(Wu et al. 2001a, Study IV). 
Nucleotide Amino acid substitution 
T80C Val27Ala 
G325A Glu109Lys 
G409T Ala137Ser 
G745A* Asp249Asn* 
G820A* Gly274Arg* 
A836G* Asn279Ser* 
G1061A* Arg354His* 
T1229G Leu410Arg 
T1313G Phe438Cys 
C1316T* Thr439Met* 
G1372A* Val458Met* 
G1378C* Val460Leu* 
A1765G* Lys589Glu* 
A1828G* Ser610Gly* 
C1918T* Pro640Ser* 
C1918G* Pro640Ala* 
C1983T Asp661Asp 
G2009A* Gly670Glu* 
T2167C* Cys723Arg* 
T2175A* Ser725Ser* 
IVS12-1* G to C, 194 bp deletion, 
termination* 
IVS12-1* G to A* 
T2270C* Leu757Pro* 
G2276A* Gly759Glu* 
C2309T Pro770Leu 
C2480T* Ala827Val* 
* Polymorphisms  
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possible truncating variant (IVS12-1 G/A). Three of the variants (Ala137Ser, Phe438Cys, 
silent Asp661Asp) were detected in CRC patients but not in controls, and thus, the role of 
two amino acid changing variants in CRC could not be excluded (Table 7). The 
Ala137Ser alteration was found in a Norwegian patient from a late onset CRC family and 
the Phe438Cys variant in a Norwegian patient from a family fulfilling the revised 
Amsterdam criteria. The fourth new variant Ala827Val was found in both a CRC sample 
and a control and was considered a polymorphism. 
 
Both MSI and MSS tumour-harbouring patients with or without family histories as well 
as patients with late onset tumour development were used to cover different CRC groups. 
CRC susceptibility mutations could not be determined in the wide set of 989 European 
samples when compared to 1027 controls. The sample set of Wu et al. (2001a) included 
patients from 33 families fulfilling the Amsterdam criteria, 225 suspected HNPCC 
patients, and 235 controls. In these two studies, altogether seven EXO1 variants 
(Pro770Leu, Asp661Asp, Phe438Cys, Leu410Arg, Ala137Ser, Glu109Lys, Val27Ala) 
were not found in controls, and thus, their effect on CRC cannot be excluded. Six amino 
acid changes were all located in the non-conserved areas of the EXO1 protein. Val27Ala 
and Phe438Cys variants change a hydrophobic residue into a less hydrophobic one. 
Ala137Ser and Leu410Arg variants change a hydrophobic residue into a small polar 
residue and a charged residue, respectively, whereas Glu109Lys changes the charge of 
the residue. 
 
A causative role for the two variants Glu109Lys and Pro770Leu not found in controls 
was confirmed in vitro by Sun et al. (2002). Nuclease activity assays were carried out for 
eight of the EXO1 missense mutations described by Wu et al. (2001a), excluding the 
truncating variant. The sequence variants Glu109Lys and Leu410Arg resulted in loss of 
exonuclease activity. Pro640Ser, Gly759Glu, and Pro770Leu showed about 60% reduced 
binding between EXO1 and MSH2. Logically, the mutated amino acids are located in the 
MSH2 interaction domain. Mutants Val27Ala, Ser610Gly, and Pro640Ala did not show 
any phenotype. 
 
In addition to exonuclease activities and interactions with Mlh1 and Msh2, Exo1 is 
involved in repairing UV damage together with the Mre11-Rad50-Xrs2 complex 
(Tsubouchi and Ogawa 2000) and has a role in meiosis (Wei et al. 2003). With further 
studies, the role of specific mutations in different pathways is expected to be elucidated 
(Sun et al. 2002). 
 
In conclusion, it is likely that the EXO1 polymorphism is common in humans and affects 
the functions of the EXO1 protein in vitro. In humans, the function of the protein may, 
however, be modified by, for example, redundant replacement of mutated EXO1 by other 
exonucleases (Tran et al. 1999, Burdett et al. 2001). The effect of various mutations 
occurring together in different CRC-predisposing genes could modify the resultant 
phenotype. 
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4. BIALLELIC MUTATIONS IN MYH PREDISPOSE TO MULTIPLE 
ADENOMAS (V) 
 
MYH-associated polyposis has recently been added to the list of recessive inheritance 
syndromes. Compound heterozygote or homozygote mutations of MYH have been shown 
to cause polyposis and possible CRC (Al-Tassan et al. 2002, Sieber et al. 2003). In this 
study, the founder mutations (Y165C, G382D) were screened for in 1003 DNA samples 
available from a group of 1042 unselected Finnish CRC patients. Four (0.4%) patients 
were found with biallelic and five patients with heterozygous MYH mutations. All 
together, mutated MYH alleles in the population were not frequent (13/2006). Because 
mutations were not found in 424 cancer-free controls in Finland and each mutation was 
found once in 100 British controls (Al-Tassan et al. 2002), the mutated alleles in the 
normal population are rare. Comparison of the results from this study with data from the 
National Finnish Polyposis Registry revealed that MYH-associated CRC appears to be as 
common as FAP-associated CRC. FAP has been shown to account for less than 1% of all 
CRC cases (Talbot et al. 2000). In another study with unselected samples, the 
corresponding figure of biallelic MYH mutation carriers in a set of 75 sporadic CRCs was 
1.3% (Halford et al. 2003). The frequency of MYH-associated CRC was higher in that 
study than in ours, but their number of samples was also smaller. Two MYH mutations 
were screened for in our study, but the possibility of patients harbouring other MYH 
mutations must also be taken into account. 
 
In addition to the Y165C and G382D mutations, other variants of MYH have been 
reported in polyposis cases (Halford et al. 2003, Sampson et al. 2003, Sieber et al. 2003) 
(Table 8). Furthermore, some MYH variants have been detected at similar frequencies in 
CRC patients and controls (Al-Tassan et al. 2002, Halford et al. 2003, Sieber et al. 2003). 
Interestingly, Pakistanian and Indian patients were found with biallelic MYH mutations in 
Y90X and E466X, respectively; thus, specific mutations of MYH are likely to occur in 
different ethnic populations (Jones et al. 2002, Sampson et al. 2003). 
 
Abundant somatic G:C→T:A transversions in APC have been detected in MYH patients 
(Al-Tassan et al. 2002, Jones et al. 2002, Sieber et al. 2003). Here, transversion in APC 
was found in only one patient with heterozygous MYH mutation, revealing the effect of 
deficient BER. According to the study of Halford et al. (2003), biallelic MYH mutations 
also occurred without somatic APC transversions, indicating that other genes could be 
mutated. 
 
In this study, two of the four biallelic MYH mutation carriers had five or several polyps 
and two had 50-100 adenomas. Importantly, the phenotype of all biallelic MYH mutation 
carriers in the Finnish sample set was not as polypotic as in previous studies. Sieber et al. 
(2003) showed that none out of six biallelic mutation carriers had less than 18 polyps. 
They also reported that almost one-third of patients harbouring 15-100 polyps and 7.5% 
of classical polyposis patients (APC mutations excluded) were biallelic MYH mutation 
carriers. However, the numbers of mutated patients in these studies were small, and thus, 
not necessarily comparable. Sampson et al. (2003) described a compound heterozygous 
patient with only three adenomas, showing that biallelic MYH mutations can rarely cause 
only a few adenomas. More data on MYH patients are needed to distinguish the mutation 
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Table 8. Variants of MYH reported in patients with colorectal adenomas or cancer (Al-
Tassan et al. 2002, Jones et al. 2002, Halford et al. 2003, Sampson et al. 2003, Sieber et 
al. 2003, Study V). 
Nucleotide Amino acid 
substitution 
Biallelic 
mutation with 
Number of 
patients 
Number of 
adenomas in 
patient 
CRC Ethnicity 
G64A* Val22Met* - Allele freq. 
9% 
Not known Yes/No Caucasian 
T182A Val61Glu - 1 None Yes Caucasian 
C247T Arg83Stop - 1 6 Yes Caucasian 
252delG Termination 137insIleTrp 1 100-1000 Yes Caucasian 
C270A Tyr90Stop Tyr90Stop 1 >400 Yes Pakistani 
IVS5-1 G to A Tyr165Cys 1 14 No Caucasian 
T349A Trp117Arg Tyr165Cys 1 >100 No Caucasian 
411dupATGGAT 137insIleTrp nt252delG ● ● ● ● 
A494G Tyr165Cys Tyr165Cys  
IVS5-1 
Trp117Arg 
Val232Phe 
IVS10+3 
Gly382Asp 
 
nt1419delC 
- 
10 
●
 
●
 
1 
1 
16 
 
1 
several 
Numerous-1000 
●
 
●
 
100-1000 
Numerous 
Numerous-  
>1000 
18 
0-1000 
Yes/No 
●
 
●
 
No 
No 
Yes/No 
 
Yes 
Yes/No 
Caucasian 
●
 
●
 
Caucasian 
Caucasian 
Caucasian 
 
Caucasian 
Caucasian 
A625G Ile209Val - 1 100-1000 No Caucasian 
G694T Val232Phe Tyr165Cys ● ● ● ● 
G777A Arg260Gln Ser501Phe* 1 3 Yes Caucasian 
C883T Arg295Cys - 2 0-3 Yes/No Caucasian 
IVS10+3 A to C Tyr165Cys, 
Gly382Asp  
●
 
1 
●
 
Multiple 
●
 
No 
●
 
Caucasian 
C970T Gln324Stop Gly382Asp 1 >30 No Caucasian 
G972C* Gln324His* - Allele freq. 
24-29% 
Not known Yes/No Caucasian 
1103delC Termination Gly382Asp 1 70 No Caucasian 
G1145A Gly382Asp Gly382Asp 
IVS10+3 
Gln324Stop 
nt1103delC 
465del 
- 
5 
●
 
●
 
●
 
1 
several 
5-1000 
●
 
●
 
●
 
Multiple 
0-1000 
Yes/No 
●
 
●
 
●
 
Yes 
Yes/No 
Caucasian 
●
 
●
 
●
 
Caucasian 
Caucasian 
1395-7delGGA 465del Gly382Asp ● ● ● ● 
G1396T Glu466Stop Glu466Stop 4 >100- >200 Yes/No Indian 
1419delC Termination Tyr165Cys ● ● ● ● 
C1502T* Ser501Phe* Arg260Gln 
- 
 
●
 
Allele freq. 
1-3% 
●
 
Not known 
 
●
 
Yes/No 
 
●
 
Caucasian 
 
* Polymorphisms  
● Mentioned earlier in the table 
 
 
carriers from other polyposis patients. Polyp number and family history help the 
prediction of MYH-associated polyposis in most cases. Treatment to prevent CRC, 
corresponding to the number of polyps, is expected to develop over time. Interestingly, 
classical polyposis patients with biallelic MYH mutations were treated by total colectomy 
later than FAP patients (mean age 47.6 and 28 years, respectively) (Sieber et al. 2003). 
 
Only one out of five heterozygous mutation carriers had more than five polyps, whereas 
in the study of Sampson et al. (2003), three heterozygous patients had 15, 20, and 
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numerous adenomas. The second hits in MYH were absent when the tumours of these 
heterozygous patients were sequenced. Thus, it seems that the formation of adenomas can 
vary to some extent (Sampson et al. 2003). Heterozygous MYH mutation carriers have 
not been shown to have increased risk of CRC, and the risk of MYH patients or mutation 
carriers to develop other cancers or disorders has not been defined. Interestingly, the 
present study revealed various solid tumours in the families of MYH patients, and thus, 
the predisposition of MYH mutations to other types of cancers warrants investigation. 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
 
 
 
The roles of two different DNA repair systems, mismatch repair (MMR) and base 
excision repair (BER), in colorectal cancers (CRC) were investigated. Germline 
mutations of genes acting on the MMR and BER systems have previously been shown to 
cause hereditary non-polyposis colorectal cancer (HNPCC) and MYH-associated 
polyposis, respectively. To further evaluate the defects in MMR, phenotypically normal 
tissues of MLH1-/- patient were studied, candidate microsatellite instability target genes 
were sought in CRCs, and the involvement of MMR genes MLH3 and EXO1 in CRC was 
elucidated. Moreover, the defective BER and the phenotype of MYH mutation carriers 
were evaluated by searching for founder mutations in an unselected, population-based set 
of CRC samples. 
 
1. MMR-deficient normal phenotype tissues showed that a large number of 
mutations occur without a visible tumour. The molecular tumour clock model 
helps to clarify the genetic changes in cells before tumour formation and the time 
required for the accumulation of occult mutations. This model can be used in 
studies on the characters of different MMR-deficient, phenotypically normal 
tissues as well as tumours. 
 
2.  A new microsatellite instability target gene candidate CtIP was proposed, and the 
length of intronic mononucleotide repeats was found to affect the frequency of 
repeat background mutations. Knowledge of different mutated cellular pathways 
leading to tumour formation is essential for understanding the behaviour of cancer 
and assigning specific treatments. Thus, increasing data on microsatellite 
instability target genes could shed light on the mutation spectrum of MMR-
deficient tumours. 
 
3.  Neither MLH3 nor EXO1 seemed to occur frequently in colorectal tumour 
formation. Mutations in different mismatch repair genes can explain some of the 
HNPCC or sporadic colon tumours. Some as yet unidentified genes in the MMR 
system may also have a role in colon tumour formation. Discovery of these 
MMR-related genes, followed by detection of harboured mutations could provide 
new insights into the biology of tumours. 
 
4.  Biallelic MYH mutations were found in Finnish CRC patients, and these biallelic 
mutation carriers had more polyps than patients with only one mutated allele. The 
usefulness of MYH mutation screening of CRC patients and the optimal treatment 
for MYH-associated polyposis patients need to be evaluated. Characterization of 
the phenotype of mutation carriers could help to identify the syndrome. The 
cancer risk of heterozygous mutation carriers should also be determined. 
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